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In this research, we develop and apply causal inference methods for the field of infectious
diseases. In the first part of this research, we consider an inverse probability (IP) weighted
Cox model to estimate the effect of a baseline exposure on a time-to-event outcome. IP
weighting can be used to adjust for multiple measured confounders of a baseline exposure
in order to estimate marginal effects, which compare the distribution of outcomes when the
entire population is exposed versus the entire population is unexposed. IP weights can also
be employed to adjust for selection bias due to loss to follow-up. This approach is illustrated
using an example that estimates the effect of injection drug use on time until AIDS or death
among HIV-infected women.
In the second part of this research, we develop and apply methods for generalizing trial
results for continuous data. In a randomized trial, assuming participants are a random sample
from the target population may be dubious. Lack of generalizability can arise when the
distribution of treatment effect modifiers in trial participants is different from the distribution
in the target. We consider an inverse probability of sampling weighted (IPSW) estimator for
generalizing trial results to a user-specified target population. The IPSW estimator is shown
to be consistent and asymptotically normal. Expressions for the asymptotic variance and a
consistent sandwich-type estimator of the variance are derived. Simulation results comparing
the IPSW estimator to a previously proposed stratified estimator are provided. The IPSW
estimator is employed to generalize results from the AIDS Clinical Trials Group (ACTG) to
all people currently living with HIV in the U.S.
In the third part of this research, we develop and apply methods for generalizing trial
iii
results for right-censored data. The IPSW estimator is considered for right-censored data
and is defined as an inverse weighted Kaplan-Meier (KM) estimator. Simulation results
are provided to compare this estimator to an unweighted KM estimator and a stratified
estimator. The average standard error is computed using a nonparametric bootstrap. The
IPSW estimator is employed to generalize survival results from the ACTG to all people
currently living with HIV in the U.S.
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CHAPTER 1: INTRODUCTION
In this research, we develop and apply causal inference methods for the field of infectious
diseases. In the first part of this research, we consider inverse probability (IP) weighted Cox
models as an alternative to the standard Cox model. Survival analysis can be used in infectious
disease research to compare the time to occurrence of clinical events between treatment or
exposure groups (Cole and Hudgens, 2010). Randomized trials are the gold standard to
estimate exposure effects on survival time, but are not always ethical or feasible. Although
observational studies may provide estimates of effects when trial data are unavailable, the
estimates they yield are often riddled with confounding (Greenland and Morgenstern, 2001).
Informally, confounding occurs when the exposure and outcome share a common cause. The
Cox proportional hazards regression model (Cox, 1972), the standard approach in survival
analysis, can account for multiple measured confounders. As an alternative to the standard
Cox model, we present a method in Chapter 3 that uses IP weights to estimate the effect of a
baseline exposure on survival time. Under certain assumptions, results from an IP-weighted
Cox model of observational data can be interpreted similar to a randomized trial with no
drop out (i.e., loss to follow-up).
In the second part of this research, we develop and apply methods for generalizing trial
results for continuous data. Results obtained in randomized trials may not generalize to a
target population. Ideally, trial participants are a random sample from a target population
and the treatment assignment mechanism is known to the analyst. In a randomized trial,
the treatment assignment mechanism is always known, but trial participants are often a
non-random sample from a target population. Lack of generalizability can arise when the
distribution of treatment effect modifiers in trial participants is different from the distribution
in a target population. Following Cole and Stuart (2010) and Stuart et al. (2011), we consider
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an inverse probability of sampling weighted (IPSW) estimator for generalizing trial results
to a target population. In Chapter 4, the IPSW estimator is shown to be consistent and
asymptotically normal. Expressions for the asymptotic variance and a consistent sandwich-
type estimator of the variance are also derived.
In the third part of this research, we develop and apply methods for generalizing trial
results for right-censored data. In Chapter 5, the IPSW estimator is considered for right-
censored data and is defined as an inverse weighted Kaplan-Meier (KM) estimator. Simulation
results are provided to compare this estimator to an unweighted KM estimator and a stratified
estimator. The average standard error is computed using a nonparametric bootstrap and
performance is evaluated empirically. The IPSW estimator is employed to generalize survival
results from the acquired immunodeficiency syndrome (AIDS) Clinical Trials Group (ACTG)
to all people currently living with human immunodeficiency virus (HIV) in the U.S.
2
CHAPTER 2: LITERATURE REVIEW
2.1 Classical Causal Inference
Public health researchers are often interested in estimating causal effects of treatment or
exposures using data from randomized clinical trials (RCTs) or observational studies. Causal
inference is a paradigm to estimate effects and is often framed using potential outcomes
(Little and Rubin, 2000). A potential outcome is defined as the outcome that would have
been observed had a participant (possibly contrary to fact) been exposed to a certain level
of treatment or exposure. In general, Y x is potential outcome under treatment X = 1 or
lack of treatment X = 0. These potential outcomes are also referred to as factuals and
counterfactuals in the literature (Morgan and Winship, 2007). This framework allows for ex-
tensions beyond the randomized trial to accommodate scenarios such as observational studies,
noncompliance, or missing data (Holland, 1986; Robins and Finkelstein, 2000; Rubin, 1990).
The notation of potential outcomes is historically related to Neyman’s randomization-based
inference (Neyman et al., 1992; Rubin, 1990; Robins, 1989). Once a participant is assigned
to treatment, only one of the two potential outcomes is observed; thus, the problem of causal
inference is akin to a missing data problem.
There are two randomization-based approaches to causal inference developed by Fisher
(Fisher, 1973; Rubin, 1980) and Neyman et al. (1992). Using the Fisher approach, the sharp
null hypothesis is evaluated, which states that the outcome is the same for both treatment
groups for all participants (i.e., Y 1i = Y
0
i ), where i indexes the study participants. Under
the sharp null hypothesis, all information can be identified from the observed data (i.e.,
Y 1i = Y
0
i = Yi) and test statistics and P values can be computed. Little and Rubin (2000)
argued that this approach is limited because the null hypothesis is restrictive and significant
tests may not be clinically meaningful.
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In Neyman’s approach to causal inference, expectations of statistics are evaluated with
respect to the distribution of the assignment mechanism and confidence intervals are calcu-
lated for the average causal effect (Little and Rubin, 2000). This idea is historically related
to Neyman’s randomization-based inference in surveys (Neyman et al., 1992). An unbiased
estimator of the causal estimand and an unbiased (or upwardly biased) estimator of the vari-
ance is derived. The central limit theorem allows for the construction of confidence intervals.
Let Y¯ 1 and Y¯ 0 be the averages of the potential outcomes in the population. Let y¯1 and y¯0
denote the sample means among those assigned to treatment and control, respectively. Let
n1 denote the number assigned to treatment, n0 denote the number assigned to control, s
2
1
denote the variance among those assigned to treatment, and s20 denote the variance among
those assigned to control. The estimated variance is se2 = s21/n1 +s
2
0/n0. The 95% confidence
interval for the average treatment difference (Y¯ 1 − Y¯ 0) is (y¯1 − y¯0) ± 1.96 × se. Neyman’s
approach to causal inference is commonly used in epidemiological studies and is employed
throughout this research.
There are several assumptions necessary to estimate causal effects. First, there needs to
be no interference between participants and treatment variation irrelevance needs to hold
(i.e., stable unit treatment value assumption (SUTVA)) (Rubin, 1980). This means that the
potential outcomes for any participant do not vary with the treatments assigned to other par-
ticipants, and, for each participant, there are no different forms or versions of treatment which
lead to different potential outcomes. This implies that the study design needs a well-defined
treatment assignment mechanism (Robins et al., 2000), so there are not multiple versions
of exposure, or if there are, they are unimportant (Cole and Frangakis, 2009; Pearl, 2010;
VanderWeele, 2009a). In general, consistency always holds (i.e., Y = Y 1X +Y 0(1−X)). We
must have measured enough variables so that we can effectively address confounding (Robins
et al., 2000). Effectively addressing confounding can lead to exchangeability, which means the
potential outcomes are independent of the exposure. In other words, the exposure assignment
mechanism depends only on the data through the measured covariates and outcome (Little
and Rubin, 2000). Confounders are variables associated with the exposure and independent
risk factors for the outcome that are not affected by exposure (Greenland and Morgenstern,
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2001). Informally, confounding occurs when exposure and outcome share a common cause.
In a trial, exchangeability is gained through randomization. Lastly, the conditional proba-
bility of receiving every level of treatment given covariates must be greater than zero (i.e.,
positivity) (Cole and Hernan, 2008).
Randomization of exposure allows for straightforward estimation of causal effects. In a
completely randomized design, exposure is not associated with any potential confounders.
Estimation of causal effects is not possible when there is unmeasured confounding. In many
public health studies, it is not ethical or feasible to randomize the treatment or exposure.
Principles of causal inference can be applied to estimate effects in observational studies in the
presence of (measured) confounding. In section 2.2, we present the literature for IP-weighted
Cox models, which is one approach to applying causal inference methods to estimate effects
with observational data.
Causal inference methods can also be employed to sharpen inference from randomized
trials. Informative censoring and generalizability of results are two possible concerns in trials
(Cole and Stuart, 2010; Stuart et al., 2011; Frangakis and Rubin, 1999). A recent paper by
Hernan et al. (2013) discussed how randomized trials may be subject to post-randomization
selection bias and confounding, particularly for studies with longer follow-up. The authors
argued that intention-to-treat analyses may not always be estimating the effects of inter-
est. The authors also proposed a set of g-methods, including inverse probability weighting
methods. In Section 2.3, we present the literature for generalizing trial results, highlighting
recently proposed methods using sampling scores.
2.2 Inverse Probability Weighted Cox Models
The Cox proportional hazards regression model (Cox, 1972) is the standard approach
to account for multiple measured confounders in observational studies with separate curves
presented for each baseline covariate group. As an alternative to the standard Cox model, IP
weights can be utilized to estimate the effect of an exposure that is fixed at study entry (Cole
and Hernan, 2004; Nieto and Coresh, 1996; Xie and Liu, 2005). IP weighting creates a pseudo-
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population in which confounders are no longer associated with the exposure. Under certain
assumptions, results from an IP-weighted Cox model of observational data can be interpreted
similar to results from a randomized trial with no drop out (i.e., loss to follow-up). One curve
represents the survival if everyone (possibly contrary to fact) had been exposed at baseline,
while the other curve represents the survival if no one (possibly contrary to fact) had been
exposed at baseline (Cole and Hernan, 2004; Xie and Liu, 2005). Herein, we refer to IP
weighting as standardization, where the standardization is to the entire population under two
different exposures (Cole and Hernan, 2004; Sato and Matsuyama, 2003).
An IP-weighted Cox model is fit by maximizing a weighted partial likelihood accounting for
confounding and possibly informative drop out measured by covariates through the estimated
IP weight wˆi(t). The estimated IP weight wˆi(t) is the product of an estimated time-fixed IP
exposure weight wˆ1i(t) and an estimated time-varying IP drop out weight wˆ2i(t) for each
participant i at each survival time t. If certain assumptions are met, IP weighting can
account for confounding and selection bias due to drop out by multiple covariates using
both exposure and drop out weights. Standardized survival curve estimates can be obtained
by fitting an IP-weighted Cox model stratified by exposure with no covariates and then
nonparametrically estimating the baseline survival functions for the two strata, which are
(asymptotically) equivalent to Kaplan-Meier estimates in the absence of weighting (Cole and
Hernan, 2004; Collett, 2003).
The standardized (i.e., IP weighted) method provides potential benefits that the covariate-
adjusted method lacks. First, results from the standardized approach can be used to mimic
a randomized trial when only observational data is available (under certain assumptions). In
particular, the estimated hazard ratio using the standardized approach can be interpreted the
same as the (marginal) hazard ratio one would obtain in a randomized experiment such as a
clinical trial where there is no drop out. In contrast, a covariate-adjusted Cox model hazard
ratio does not necessarily equal the marginal hazard ratio (even in the absence of confounding)
because the Cox model is not collapsible for the hazard ratio parameter (Greenland, 1996).
A regression model is said to be collapsible for a parameter (in this case, the hazard ratio) if
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the covariate-adjusted parameter is the same as the unadjusted parameter (Greenland et al.,
1999b).
Second, the IP weighting approach yields standardized survival curve estimates. Although
the hazard ratio is a common summary parameter to compare survival distributions between
exposure groups, there are drawbacks to focusing inference on hazard ratios. For instance, the
hazard ratio can be difficult to interpret, especially when trying to summarize the effect of a
treatment or exposure (Hernan, 2010). Presenting estimated survival curves is an alternative
to reporting hazard ratios that may be more interpretable because survival curves summarize
all information from baseline up to any time t. The IP-weighted approach leads to Kaplan-
Meier type survival curve estimates that are standardized to the entire population under two
different exposures at baseline while accounting for confounding by multiple covariates. A
covariate-adjusted Cox model does not afford such survival curve estimates (Cole and Hernan,
2004; Xie and Liu, 2005).
Third, the IP-weighted approach with drop out weights requires a weaker assumption
about censoring than the covariate-adjusted Cox model. Specifically, if there are measured
time-varying covariates predictive of censoring and survival time, the IP-weighted approach
will yield consistent estimates of the marginal hazard ratio, while the covariate-adjusted Cox
model estimator will not be consistent for the marginal or conditional hazard ratio (Hernan
et al., 2000; Robins et al., 2000; Robins and Finkelstein, 2000).
When interest focuses on exposures that change over time, methods must be adapted
accordingly. When a time-varying confounder is a risk factor for the outcome, predicts later
exposure, and is affected by prior exposure, standard statistical methods (e.g., Cox models
with endogenous time-varying covariates) are biased and fail to provide consistent estimators
of effects (Cole et al., 2003; Hernan et al., 2001, 2013; Robins et al., 2000). IP weighting can
be generalized to account for time-varying confounders (Robins et al., 2000). For example, in
HIV-infected individuals, CD4 count is a risk factor for death, predicts subsequent treatment
with antiretroviral therapy, and is affected by prior treatment; thus, the IP-weighted Cox
model is appropriate for studying the effect of time-varying antiretroviral therapy on overall
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survival while adjusting for time-varying CD4 count.
There are several papers that provide theoretical justification and illustrative examples for
IP-weighted Cox models. Robins et al.(Robins, 1998; Robins et al., 2000) demonstrated that
the parameters of a marginal structural model can be consistently estimated using IP-weighted
estimators. Hernan et al. (2000) provided an illustrative example using these methods to
adjust for time-varying confounding to estimate the causal effect of zidovudine on the survival
of HIV-infected men. A subsequent paper presents the use of these models to estimate the
joint effect of two treatments (Hernan et al., 2001). Cole et al. (2003) employed IP-weighted
Cox models to estimate the effect of highly active antiretroviral therapy on time to AIDS or
death, which appropriately adjust for time-varying confounders affected by prior treatment
or exposure. A subsequent paper provided additional guidelines on how to construct inverse
probability weights (Cole and Hernan, 2008). Other efforts have been made to increase the
understanding and utilization of causal inference methods among researchers (Petersen et al.,
2006). In Chapter 3, we continue this effort by demonstrating how IP-weighted Cox models
can be used to account for multiple measured confounders and selection bias due to drop
out and providing graphical summaries of these effects. This approach is compared to a
traditional Cox model and illustrated using an example that estimates the effect of injection
drug use on AIDS-free survival among HIV-infected women.
2.3 Generalizability of Randomized Trials
Results obtained in RCTs may not generalize to target populations due to differences in
characteristics between participants in the trial and target population, as well as the presence
of effect modification by these same characteristics (Cole and Stuart, 2010; Stuart et al., 2011).
Valid statistical inference depends both on the treatment allocation and the mechanism of
trail participation. Ideally, both of these steps would be randomized; however, trials are often
non-random samples from a target with the treatment assignment mechanism always known
to the analyst.
Researchers are often interested in estimating a causal effect in a target population. In
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simple settings, trial results can be mapped to a target population using nonparametric
direct standardization (Rothman, 1986), which can accommodate only on a few categorical
covariates; however, when there are many covariates or some covariates are continuous, direct
standardization is no longer possible. The second part of this research addresses the situation
often seen in a clinical trial: a known treatment assignment mechanism, but non-random
selection of participants from a target population (Little and Rubin, 2000).
Generalizability is often a concern for clinical trials in public health research. One study
highlighted the overrepresentation of African-American and Hispanic women among HIV
cases in the U.S. and the limited clinical trial participation of members of these groups
(Greenblatt, 2011). Another study reviewed eligibility criteria from 32 NIH-funded RCTs
and applied those to data from the Women’s Interagency HIV Study (WIHS). Of the 20
Adult Clinical Trials Group (ACTG) trials, 28% to 68% of the WIHS cohort would have been
excluded (Gandhi et al., 2005). Historically, generalizability was assessed through comparisons
of characteristics between the trial and target populations or comparisons of effects across
various study samples (Weisberg et al., 2009). Recent developments in the literature have
proposed novel quantitative approaches to evaluate generalizability of effects.
2.3.1 Definitions and Background
We define generalizability as the degree to which an internally valid measure of effect
estimated in a sample from one population would change if the study had been conducted in
a different target population. We view the terms “transportability” and “external validity”
as synonymous with our definition of generalizability, although Pearl defines transportability
specifically for the case where investigators would like to apply the results from a RCT to a
population in which only an observational study is feasible or ethical (Bareinboim and Pearl,
2013).
In public health research, investigators would ideally like to estimate a treatment effect
in a target population. In practice, a study sample is typically obtained from a source
population that is likely different from the target and that information is used to estimate
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effects (Rothman, 1986). The source population is often chosen instead of a target population
due to such reasons as financial or time constraints and ethical considerations. The target
population may be defined prior to designing or implementing a specific study, or researchers
may be interested in drawing inference from a published study to a different target population.
In any evaluation of generalizability, it is necessary to clearly define the target population.
The sample average treatment effect (SATE) is the average treatment effect in the source
population and the population average treatment effect (PATE) is average treatment effect
in the target population (Stuart et al., 2011, 2014).
In an ideal randomized trial (i.e., assuming no confounding, full adherence to treatment,
perfect blinding, no loss to follow-up), or in an observational study where the estimate of effect
is identifiable (i.e., assuming exchangeability between the exposed and unexposed conditional
on measured covariates, consistency within the study population, and a positive probability
of exposure within each strata of covariates), the estimator in the study sample will be an
unbiased estimate of the SATE, which we define as internal validity. Evaluation of general-
izability should not be entertained unless the results are internally valid. Even under these
ideal circumstances when our estimator is internally valid, the SATE may not be equal to
the PATE (i.e., a lack of external validity). Results obtained in one study may not gener-
alize to target populations due to 1) differences in the distribution of effect modifiers in the
study population and target population; 2) the presence of interference; or 3) the existence of
multiple versions of treatment (Bareinboim and Pearl, 2013; Hernan and VanderWeele, 2011;
Stuart et al., 2011). In this research, we assume there is no interference and only one version
of treatment, so we can focus on the scenario where the distribution of effect modifiers in the
source population differs from the target population.
Most discussions of generalizability of trial results limit themselves to considering whether
the study sample was representative of the target population. However, we suggest that a
simple comparison of the distribution of characteristics between the study sample and target
population is insufficient. An understanding of the characteristics that influence trial par-
ticipation and modify the effect of interest is essential. Rothman et al. (2013) argues that
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a representative sample is not necessary for generalizing estimates of causal effects if effects
are homogeneous. Further, “it is not representativeness of the study subjects that enhances
generalization, [but rather] it is knowledge of specific conditions and an understanding of
mechanism that makes for a proper generalization” (Rothman et al., 2013). While the easiest
and most efficient way to ensure generalizability to a specified target population is to ensure
that a trial is a representative sample of the target (Stuart et al., 2011), without an under-
standing of factors that modify the effect of interest, the effect estimate from that trial may
not be generalizable to target populations of interest.
Lack of generalizability assumes that there are two true estimates of effect (SATE and
PATE) that may be different, even if the estimator of the SATE is unbiased (Stuart et al.,
2014). In order for the SATE to be equal to the PATE, the following assumptions must hold:
no effect modification by the characteristic related to trial participation, no interference, and
treatment variation irrelevance. The first assumption means that the treatment effects are
homogeneous or covariates related to trial participation are distinct from the treatment effect
modifiers (Tipton, 2013). The last two assumptions mean that there is no interference of
participants within the trial (i.e., the potential outcomes of one participant are assumed to
be unaffected by the treatment assignment of other participants) and that there is only one
version of treatment, or if there are multiple versions, they are irrelevant for the outcome
(Rubin, 1980).
Several additional assumptions are needed to generalize trial results to target populations.
Once in the trial, participants are randomly assigned to a study arm, so that participants
from either treatment group are balanced in that covariate distribution is the same regardless
of treatment assignment conditional on trial participation. This is the ignorable treatment as-
signment mechanism. We also assume an ignorable trial participation mechanism conditional
on covariates. This means that participants in the trial are no different from nonparticipants
in regards to the treatment-outcome relationship conditional on covariates. There are not
multiple versions of treatment, or if there are, they do not affect the outcome (Cole and Fran-
gakis, 2009; Pearl, 2010; VanderWeele, 2009a). Trial participation and treatment positivity
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assumptions are also necessary (Cole and Hernan, 2008).
The easiest way to allow for generalizability is to ensure that a trial is a representative
sample of the target in regards to the treatment effect modifiers (Stuart et al., 2011). How-
ever, this is not always feasible or appropriate. New methods make it possible to use less
representative sampling for maximal internal validity, and reweight the effect estimate for
improved external validity, assuming that all treatment effect modifiers are known and the
distribution of those same characteristics is available in the target population.
2.3.2 Sampling Score Methods to Generalize Trial Results
There are several sampling-score methods to generalize an estimate from a trial to a
target population. The sampling score is defined as the probability of inclusion in the trial
given some function of covariates (Z) that are both effect modifiers and associated with trial
participation (S = 1). The effect in the target population can be estimated using sampling
scores, including matching (Stuart et al., 2011), stratification (Tipton, 2013) and an inverse
probability of sampling weighted (IPSW) estimator (Cole and Stuart, 2010; Stuart et al.,
2011).
Cole and Stuart (2010) proposed a method to standardize trial results to a target popula-
tion using an IP-weighted Cox model with sampling score weights. In the illustrative example,
results from ACTG 320 were generalized to all people living with HIV in the U.S. in 2006.
Characteristics of the target population were ascertained using estimates from the Centers for
Disease Control (CDC). The proposed inverse probability of sampling weights were defined
as P (S = 1)/P (S = 1|Z), where the sampling scores were estimated using logistic regression.
The Cox proportional hazard model was inverse weighted by these sampling scores to obtain a
hazard ratio and estimates of the marginal survival curves in the target population. A robust
estimate of the variance was employed (Robins, 1998); however, no closed-form expression
for the variance was provided. Using the IP-weighted Cox model with sampling weights, the
trial results applied to the target population, but were attenuated towards the null. In simu-
lations with a heterogeneous treatment effect, an intent-to-treat estimator was biased and the
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corresponding confidence interval had poor coverage; whereas, the proposed estimator was
unbiased and its corresponding confidence interval had appropriate coverage. The authors
provided an expression for the bias of the intention-to-treat estimator when the parameter
of interest is a difference in means and a proof that an inverse probability weighted estima-
tor is unbiased for the mean of the potential outcomes in the target population; however,
consistency and asymptotic normality of the proposed estimator were not formally shown.
In a subsequent paper by Stuart et al. (2011), sampling-score methods were used to
quantify the similarity between trial participants and those in a target population. These
methods were also used to match, weight, and subclassify the outcomes among the controls
to a target population. The assumptions for this method were discussed, including positivity,
no unmeasured confounders, and random treatment assignment. Assuming an infinite tar-
get population, the authors provided a proof that an inverse probability weighted estimator
among control participants is unbiased for the mean of the potential outcome under con-
trol in the target population E(Y 0). However, large sample properties (i.e., consistency and
asymptotic normality) of the proposed estimator were not derived. The Positive Behavioral
Interventions Support (PBIS) study was generalized to all elementary schools in Maryland.
The sampling scores P (S = 1|Z) were estimated using logistic regression. The sampling score
difference between the trial and a target population was defined. The sampling scores were
used to inverse weight the naive estimator, produce a stratified estimator, and perform full
matching. For inverse probability weighting, each control subject was given their own weight
defined as the inverse of the sampling score. For stratification, the target population was
divided into strata according to the distribution of the sampling score (i.e., quintiles) in the
target and the weights were defined as the proportion in each stratum. The authors did not
provide expressions of the variance for either the inverse probability weighted estimator or the
stratified estimator. Full matching was performed ensuring that each subclass had at least
one member of the sample and at least one member of the target population. For the PBIS
example, the control group in the trial was comparable to the state level and the weighted
means in the trial control participants were reasonable estimators of the true means at the
state level. In Stuart et al. (2014), differences between external and interval validity were
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elucidated and an overview of existing methods for generalizability was provided, including
an illustrative example of generalizing results from the PBIS study.
Tipton (2013) proposed a stratified sampling score estimator, including a discussion of the
necessary assumptions. This estimator was computed in the following steps. The sampling
scores were used to create strata in the target population (e.g., defined by quintiles). The
weight was defined as the proportion within each stratum in the population. The difference
between the treated and untreated within each stratum was weighted and the weighted differ-
ences were summed across strata. Tipton also developed expressions for bias reduction and
variance inflation as compared to the intention-to-treat estimator in the trial (Tipton, 2013).
Tipton extended this method by proposing a stratified sample recruitment approach based on
the sampling scores, which requires identification of the target population and trial eligibility
criteria (Tipton et al., 2014). A related paper discussed the application of this estimator to
inform future trials, as well as the use of this estimator in trial design (O’Muircheartaigh and
Hedges, 2013).
The limitations of the stratified sampling score estimator compared to the IP-weighted
estimator include that it is coarser (i.e., limited by the number of stratum defined by the
sampling score) and it does not have the interpretation of creating a pseudo-population. The
stratified estimator does not always immediately allow for estimation of marginal effects,
which is the average effect comparing the target population where everyone (possibly con-
trary to fact) was exposed to the target population where no one (possibly contrary to fact)
was exposed (Kaufman, 2010; Lunceford and Davidian, 2004). The sampling score stratified
estimator may be biased when there is residual confounding within strata (e.g., Z is continu-
ous), as the estimator based on stratification is not consistent for the PATE (Lunceford and
Davidian, 2004). On the other hand, the IP-weighted estimator is sensitive to model specifi-
cations (i.e., assumes the sampling score model is correctly specified) and has been shown to
perform poorly when sampling probabilities are small (Kang and Schafer, 2007).
Results in Chapter 4 continue this effort by considering an IP-weighted estimator for a
difference of means in the target population, where the weights are defined as the inverse
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of the sampling score. This estimator is shown to be consistent and asymptotically normal.
Expressions for the asymptotic variance and a consistent sandwich-type estimator of the
variance are also derived. The performance of the IP-weighted estimator is compared to a
previously proposed stratified estimator in a simulation study.
2.3.3 Other Methods to Generalize Trial Results
Greenhouse et al. (2008) described and illustrated an approach for determining if results
from a randomized trial are generalizable. They outlined a methodological approach using
four steps: identify data sources, subset the data on demographic variables to allow com-
parisons to a target population, measure the outcome, and perform sensitivity analysis. The
authors provided an illustrative example assessing the risk of suicidality among pediatric
antidepressant users. A meta-analysis of RCTs demonstrated an increased risk and obser-
vational studies did not confirm that result (i.e., showed a decreased risk). One explanation
is that the two studies were sampling from different populations (i.e., trial exclusion criteria
could limit the representativeness of the trial sample). There could be treatment hetero-
geneity based on variables related to trial participation. In that case, generalizability of the
results without adjustment may not be appropriate. In the illustrative example, the goal was
to assess the representativeness of the trial participants. The rate of suicidal ideation and sui-
cidal behaviors in the depressed adolescents who participated in the RCTs was approximately
one-half the adjusted rate among depressed adolescents in the United States. The authors
posit that exclusion of those at high risk of the event could lead to an upwardly biased rate
ratio (Greenhouse et al., 2008). Although Greenhouse et al. (2008) highlighted this issue,
their approach only allows for determining if results are generalizable or not, and does not
posit a solution for the latter.
Some initial approaches to this problem have been suggested; however, they are limited in
the scope of their application. Weisberg et al. (2009) suggested using four stratum of outcome
and treatment types (doomed, immune, causal and preventive), then defined an expression
for the bias using these stratum. A doomed individual will experience the event of interest
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regardless of which treatment is received; an immune individual will be spared in either
instance; a causal individual experiences the event only if assigned to the treatment group;
and a preventive individual, only if assigned to the control. Each stratum had a population
proportion (P ) and a selection probability (S). The risk ratio in the target population was
defined as RRtar = (P1 + P2)/(P1 + P3). The observed risk ratio in the RCT was defined as
RRobs = (S1P1 + S2P2)/(S1P1 + S3P3). If the the trial selection mechanism is not ignorable
(i.e. selection is related to an individual’s risk of an event), the value of RRtar will be
different from RRobs. The authors proposed that when participants at high risk are more
likely to be excluded, there may be an upwardly biased relative risk estimate for the true
relative risk in the target population; whereas, if those at a lower risk are more likely to be
excluded, there may be a downwardly biased estimate of the relative risk (Weisberg et al.,
2009). The framework suggested by Weisberg et al. (2009) is useful, but limited to binary
data. Extensions are necessary to accommodate other types of data, such as right-censoring,
commonly seen in RCTs.
Frangakis suggested a principal stratification approach to adjust for differences in post-
treatment effects between the participants in a RCT and participants in an observational study
(Frangakis, 2009). Principal stratification was initially used to compare treatments adjusting
for post-randomization variables to account for selection bias (Frangakis and Rubin, 2002).
Using this approach, causal effect are estimated within strata defined by cross-classification of
participants by the joint potential outcomes of the post-randomization variable under treat-
ment and control. It is appropriate to condition on the principal strata because they are not
affected by treatment (Hudgens et al., 2003; Hudgens and Halloran, 2006). Principal strati-
fication could be applied to address generalizability when a target population has a different
distribution of principal strata (defined by intermediates on the causal path between exposure
and outcome that contain information on both the treatment and individual differences) than
the source population. An illustrative example of a trial with different treatment compli-
ance rates from a target population is provided. A limitation of this approach is that the
distribution of the outcome within principal strata must be known in the source and target
populations (Frangakis, 2009).
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Another related concept in the literature is transportability. A recent paper examined the
transportability of effects of compound treatments (Hernan and VanderWeele, 2011). Com-
pound treatments are defined as treatments with multiple versions (i.e., multiple realizations
of the treatment can be mapped onto one value). Transportability is a question of estimating
the average causal effect in a target population that is different from the source population.
Transportability of compound treatment effects depends on effect modification, interference,
and versions of compound treatment. The authors provided an expression for the counterfac-
tual mean when versions of compound treatment are known for those in the source population,
which requires all information on versions of compound treatment in the target population
for estimation. Determining the versions of compound treatment in the source population
and target population can be complicated. Versions of treatment are necessary to evaluate
exchangeability and positivity to allow for transport of effects to other populations.
Bareinboim and Pearl (2013) provided a graphical condition for evaluating transportability
and an algorithm for transportability of causal effects, which produces a transport formula
whenever those results are in fact transportable . The authors defined transportability as
“a license to transfer information learned in experimental studies to a different population,
on which only observational studies can be conducted” (Bareinboim and Pearl, 2013). The
authors provided a graphical condition for determining the transportability of causal effects.
2.4 Methods for Generalizing Right-Censored Data
Kaplan-Meier estimators are used to quantify survival distributions and are a commonly
used nonparametric estimator in survival analysis (Kalbfleisch and Prentice, 2002). If the trial
is random sample from the target population, standard methods, such as the Kaplan-Meier
estimator, are appropriate and comparisons between groups can be made with a log rank
test. However, when the trial is possibly a non-random sample from the target population,
properly weighting the observed trial data to estimate the Kaplan-Meier may be necessary.
The Kaplan-Meier estimator is also appealing because it does not require a proportional
hazards assumption or possible complications faced by hazard ratios estimated using a Cox
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proportional hazards model. The hazard ratio can be difficult to interpret, especially when
trying to summarize the effect of a treatment or exposure (Hernan, 2010).
Presenting estimated survival curves is an alternative to reporting hazard ratios that may
be more interpretable because survival curves summarize all information from baseline up to
any time t (Cole and Hernan, 2004). Robins and Finkelstein (2000) proposed an adjusted
Kaplan-Meier estimator using inverse probability (IP) of censoring weights to estimate effects
in the presence of selection bias using in randomized trial data. Xie and Liu (2005) developed
an adjusted Kaplan-Meier estimator using inverse probability of treatment weights to estimate
effects in the presence of (measured) confounding in an observational study. They presented
a method for estimating marginal survival curves, including the development of a weighted
log rank test.
Cole and Stuart (2010) proposed a method to standardize trial results to a target popu-
lation for right-censored data using an IP-weighted Cox model with sampling weights. They
reported the hazard ratios and displayed estimated survival curves from this model. A ro-
bust estimator of the variance of the hazard ratio was employed, but the performance of the
nonparametric bootstrap standard error was not evaluated. In the IP-weighted model, the
results seen in the trial applied to the target population, but were attenuated to the null.
The authors provide simulations demonstrating that the proposed estimator of the hazard
ratio was (asymptotically) unbiased and its corresponding confidence interval had coverage
around the nominal level. Research in Chapter 5 will continue this effort by considering an
IP-weighted Kaplan-Meier estimator, comparing this estimator to a stratified estimator, and
empirically evaluating the performance of the nonparametric bootstrap standard error.
2.5 Summary
In summary, a large body of literature has been developed to address concerns of (mea-
sured) confounding in observational studies. Statistical properties of the IP-weighted estima-
tors were demonstrated (Robins, 1998; Robins et al., 2000). There are several epidemiological
papers that clarified technical details and provided guidance on implementation of these mod-
18
els (Cole et al., 2003; Cole and Hernan, 2008; Hernan et al., 2000, 2001). Other efforts have
been made to increase the understanding and utilization of causal inference methods among
researchers (Petersen et al., 2006). In Chapter 3, we continue that effort by summarizing the
literature for IP-weighted Cox models through a comparison to the traditional Cox model
and an illustrative example in HIV/AIDS research.
There is a growing literature on methods for generalizing trial results; however, these
approaches do not develop the statistical properties or provide closed-form expressions for
the estimators of the variance. Following Cole and Stuart (2010) and Stuart et al. (2011), we
consider an inverse probability of sampling weighted (IPSW) estimator for generalizing trial
results to a target population in Chapter 4, where the parameter of interest is a difference
in average potential outcomes in a target population. We show that the IPSW estimator is
consistent and asymptotically normal, and provide a closed-form expression for a consistent
estimator of the variance. The IPSW estimator is employed to generalize results from the
ACTG to all people currently living with HIV in the U.S. Following Cole and Stuart (2010)
and Buchanan, et al. (In preparation), we consider an IPSW estimator for right-censored
outcomes, which is defined as an inverse weighted Kaplan-Meier estimator. In Chapter 5,
the IPSW estimator is employed to generalize survival effects from the ACTG to all people
currently living with HIV in the U.S.
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CHAPTER 3: WORTH THE WEIGHT: USING INVERSE
PROBABILITY WEIGHTED COX MODELS IN AIDS RESEARCH
3.1 Introduction
Survival analysis is often used in infectious disease research to compare the time to oc-
currence of clinical events between treatment or exposure groups (Cole and Hudgens, 2010).
Randomized trials are the gold standard to estimate exposure effects on survival time, but are
not always ethical or feasible. Although observational studies may provide estimates of effects
when trial data are unavailable, the estimates they yield are often riddled with confounding
(Greenland and Morgenstern, 2001). Informally, confounding occurs when the exposure and
outcome share a common cause. The standard approach in survival analysis to account for
multiple measured confounders is the Cox proportional hazards regression model (Cox, 1972).
As an alternative to the standard Cox model, we present a method in this paper that
uses inverse probability (IP) weights to estimate the effect of a baseline exposure on survival
time. Under certain assumptions, results from an IP-weighted Cox model of observational
data can be interpreted similar to a randomized trial with no drop out (i.e., loss to follow-
up). In particular, unlike the standard Cox model, this approach allows for estimation of
marginal effects which compare the distribution of outcomes when the entire population is
exposed versus when the entire population is unexposed (Kaufman, 2010). For example, this
IP-weighted approach yields marginal Kaplan-Meier (Kaplan and Meier, 1958) type survival
curve estimates that account for confounding by measured covariates (Xie and Liu, 2005;
Cole and Hernan, 2004). Informally, each participant is weighted to create a pseudopopula-
tion where (i) exposure is not associated with covariates such that (measured) confounding
is eliminated, and (ii) drop out is not associated with exposure or covariates such that se-
lection bias due to drop out is eliminated (Hernan et al., 2000). This approach is akin to
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survey sampling weighting used to estimate a quantity in the population (Thompson, 2012;
Horvitz and Thompson, 1952). Herein, we refer to IP weighting as standardization, where the
standardization is to the entire population under two different exposures (Cole and Hernan,
2004; Sato and Matsuyama, 2003). We illustrate this standardization method through an
example that estimates the effect of injection drug use (IDU) on AIDS-free survival among
HIV-infected women.
3.2 Motivating Example: AIDS-Free Survival Among Injection Drug Users
The Women’s Interagency HIV Study (WIHS) is a prospective, observational, multicenter
study of women living with HIV and women at risk for HIV infection in the U.S. (Bacon et al.,
2005). A total of 4,129 women (1,065 HIV-uninfected) were enrolled between October 1994
and December 2012 at six U.S. sites. An institutional review board at each site approved
study procedures and all study participants provided written informed consent. We were
interested in determining if AIDS-free survival among HIV-infected women differed by IDU,
accounting for possible confounding by factors measured at baseline and selection bias due
to drop out by factors measured during study follow-up. We estimated the hazard ratio and
the absolute risk difference at ten years to quantify this effect.
The study sample consisted of 1,164 women enrolled in WIHS who were alive, HIV-
infected, and free of AIDS on 6 December 1995 (Lau et al., 2009). The endpoint was either
death or a diagnosis of AIDS. Women who did not reach this endpoint by 6 December 2005
were censored at that time or at their last visit where they were known to be alive and AIDS-
free, whichever came first. A history of IDU at WIHS enrollment is denoted as X = 1 (X = 0
otherwise). The baseline covariates African American race, age, and nadir CD4 count (in
cells/uL) measured from WIHS enrollment to baseline (i.e., 6 December 1995) are denoted
by the vector Z. The time-varying covariate antiretroviral (ART) initiation during study
follow-up is denoted by Z(t), where Z(t) = 1 if an individual starts ART before time t since
baseline and Z(t) = 0 otherwise.
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3.3 Inverse Probability Weighted Cox Models
Researchers are often interested in estimating effects of an exposure fixed at study entry.
IP-weighted Cox models are a method to compare the timing of clinical events under two
different exposures. An appealing feature of the IP-weighted Cox model is that the results
from this method can be interpreted similar to results from randomized trials with no drop
out. An IP-weighted Cox model is fit by maximizing a weighted partial likelihood, where









where R(t) is the risk set at time t and exp(β) is the marginal hazard ratio for a unit difference
in exposure X accounting for confounding and selection bias measured by covariates through
the estimated IP weight wˆi(t) (discussed below) (Robins et al., 2000). When the estimated
IP weight wˆj(t) = 1 for all j ∈ R(t), equation (3.1) is the usual contribution to the partial
likelihood for the standard (i.e., unweighted) Cox model (See Appendix A). Slight modification
of the likelihood is needed in the presence of tied survival times. The robust variance estimator
(Lin and Wei, 1989) can be employed to account for the fact that the IP weights are estimated
(Cole and Hernan, 2008). See Appendix A for a review of inference for the standard (i.e.,
unweighted) Cox proportional hazards model.
The estimated IP weight wˆi(t) is the product of an estimated time-fixed IP exposure
weight wˆ1i and an estimated time-varying IP drop out weight wˆ2i(t) for each participant
i at each survival time t. The time-fixed IP exposure weights are constructed to account
for confounding by covariates measured at baseline. The IP exposure weights essentially
create a pseudopopulation where exposure is not associated with covariates, thus eliminating
(measured) confounding. For example, if non-African Americans are more likely to report
IDU than African Americans, then an African American in the study who reports IDU will
be upweighted because she is representing more participants. Different versions of these
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weights have been proposed. It is generally recommended to use the (estimated) stabilized IP
exposure weight wˆ1i defined as the ratio of the estimated marginal probability of having the
exposure that participant i had, formally P (Xi = xi), to the estimated covariate-conditional
probability of having the exposure that participant i had, formally P (Xi = xi|Zi), where Zi
are the measured covariates for participant i assumed sufficient to adjust for confounding.
Details on estimating the IP exposure weights using the observed data are provided in the
next section tailored to the example.
The time-varying IP drop out weights wˆ2i(t) are constructed to account for possible se-
lection bias due to drop out (Robins et al., 2000). The IP drop out weights essentially create
a pseudopopulation as if no participants had dropped out. Participants last observed alive
and AIDS-free more than one year prior to 6 December 2005 were considered drop outs.
Participants receive a time-varying weight that corresponds to their probability of remaining
free from drop out. This stabilized IP weight wˆ2i(t) is defined as the ratio of the estimated
marginal probability of remaining free of drop out, formally P (Di > t|Xi), where Di is the
time from baseline to drop out for participant i, to the estimated covariate-conditional prob-
ability of remaining free of drop out, formally P (Di > t|Zi, Zi(t), Xi), where Zi and Zi(t)
are the measured common causes of drop out and the study outcome for participant i up to
time t. (Note the covariates in the drop out model can be different than the covariates in the
exposure weight model). Details on estimating the IP drop out weights using the observed
data are provided in the next section tailored to the example.
Standardized survival curve estimates can be obtained by fitting an IP-weighted Cox
model stratified by exposure with no covariates and then nonparametrically estimating the
baseline survival functions for the two strata (Cole and Hernan, 2004). In the absence of
weighting, these survival curve estimates will be (asymptotically) equivalent to Kaplan-Meier
estimates obtained separately for each of the exposure stratum (Collett, 2003).
For all Cox models presented below, we employed Efron’s method to account for events
that occurred on the same date (Efron, 1977). We obtained confidence intervals for the
risk difference at 10 years using a nonparametric bootstrap with 200 random samples with
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replacement (Efron and Tibshriani, 1994). The data analysis for this paper was conducted
using SAS software version 9.3 (SAS Institute Inc., Cary, NC). SAS code for analyses in the
present paper is provided in the Supplemental Materials.
3.4 Illustrative Example
The 1,164 women were 58% African American, median age was 36 years, and median
nadir CD4 count was 349 cells/µL at baseline (Table 3.1). At enrollment, 38% of women
reported a history of IDU. During follow-up, 664 (57%) of women initiated ARTs. Women
were followed for up to 10 years with a total of 7,090 person-years during which 579 (50%)
developed AIDS or died, and 117 (10%) dropped out of the study. In analyses that did not
account for covariates, women with a history of IDU had notably worse AIDS-free survival
than women without a history of IDU (Figure 3.1). The estimated hazard ratio from the
unadjusted Cox model was 1.72 (95% confidence interval (CI): 1.46, 2.03; Wald P value <
0.001), suggesting that the hazard of AIDS or death for those with a history of IDU was almost
twice the hazard of those without a history of IDU (Table 3.2). We assessed the proportional
hazards assumption graphically by examining whether the log cumulative hazard function
estimates (See Figure 3.2) were approximately parallel. We also assessed this assumption
statistically by inclusion of a product term between history of IDU and time in the Cox
model, for which the Wald P value was 0.40. Neither graphical nor statistical assessment
suggested a meaningful departure from proportional hazards.
We then obtained a standardized hazard ratio estimate from the IP-weighted Cox model,
which involved two steps. In the first step, using separate logistic regression models, weights
were estimated for the probability of exposure (i.e., history of IDU) and for the probability
of not dropping out. For the exposure weights, we fit logistic regression models for both the
numerator and denominator. The exposure model for the numerator had no covariates, while
the exposure model for the denominator included age at baseline, race, and nadir CD4 count,
as well as all pairwise interactions. Age and nadir CD4 were included as continuous variables
using restricted quadratic splines with four knots placed at 5th, 35th, 65th, and 95th percentiles
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(Howe et al., 2011b). For the drop out weights, time was coarsened into months since baseline
(Hernan et al., 2001). Then, using pooled logistic regression (D’Agostino et al., 1990), the
drop out model for the numerator included only exposure (i.e., history of IDU) and time
(using restricted quadratic splines), while the drop out model for the denominator included
exposure, time (spline), age (spline), race, nadir CD4 count (spline), and ART initiation
(time-varying), as well as all pairwise interactions. In the pooled logistic regression model,
each person contributed up to 120 records and the weights were cumulatively multiplied for
each person. The estimated weights wˆi(t) had a mean of 1.01 (with a standard deviation of
0.76), and ranged from 0.43 to 12.43 (see Table 3.3). In the second step, the IP-weighted
Cox model was fit by weighting participants by their estimated weights, with outcome time
to AIDS or death, and history of IDU as the sole covariate.
We obtained the estimated survival functions from an IP-weighted Cox model with no
covariates stratified by history of IDU. After standardization for confounding and drop out by
IP weighting, survival curves showed an attenuated difference in AIDS-free survival compared
to the survival curves without accounting for any covariates (Figure 3.1). Under certain
assumptions discussed below, the dashed black curve can be interpreted as an estimate of the
AIDS-free survival if (contrary to fact) everyone had a history of IDU at enrollment and did
not drop out, while the solid black curve can be interpreted as an estimate of the AIDS-free
survival if (contrary to fact) no one had a history of IDU at enrollment and everyone did not
drop out (6, 7). The standardized hazard ratio from the IP-weighted Cox model was 1.53 (95%
CI: 1.26, 1.85; Wald P value < 0.001) (Table 3.2). We again assessed the proportional hazards
assumption graphically by examining whether the IP-weighted log cumulative hazard function
estimates (See Figure 3.3) were approximately parallel. We also assessed this assumption
statistically by inclusion of a product term between history of IDU and time, for which the
Wald P value was 0.18. Neither graphical nor statistical assessment suggested a meaningful
departure from proportional hazards. From the standardized survival curves, the ten-year risk
of AIDS or death was 0.59 if (contrary to fact) everyone had a history of IDU at enrollment
and 0.46 if (contrary to fact) no one had a history of IDU at enrollment. The 10-year risk
difference was 0.14 (bootstrap 95% CI: 0.06, 0.22). For comparison, we also estimated a
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covariate-adjusted hazard ratio by including history of IDU, age (spline), race, and nadir
CD4 count (spline) directly in an unweighted Cox model. The covariate-adjusted hazard
ratio estimate was 1.62 (95% CI: 1.35, 1.95; Wald P value < 0.001).
3.5 Discussion
IP-weighted Cox models and standardized survival curves were presented as methods to
compare the timing of clinical events for two different exposure conditions under certain
assumptions. We compare this method to the traditional Cox model and discuss assumptions
and caveats below.
Although hazard ratio estimates from the IP-weighted and covariate-adjusted Cox model
were comparable in the WIHS example above, the standardized (i.e., IP-weighted) method
provides several potential benefits over the covariate-adjusted Cox model. First, the results
from the standardized approach may be interpreted similar to results from a randomized
trial with no drop out when only observational data is available (under certain assumptions
discussed below). In particular, the estimated hazard ratio using the standardized approach
can be interpreted the same as the (marginal) hazard ratio one would obtain in a randomized
experiment such as a clinical trial where there is no confounding and no drop out. In con-
trast, a covariate-adjusted Cox model hazard ratio does not necessarily equal the marginal
hazard ratio because (even in the absence of unmeasured confounding) the Cox model is not
collapsible for the hazard ratio parameter (Greenland, 1996). A regression model is said to be
collapsible for a parameter (in this case, the hazard ratio) if the covariate-adjusted parameter
is the same as the unadjusted parameter (Greenland et al., 1999b).
Second, the IP weighting approach yields standardized survival curve estimates. Although
the hazard ratio is a common summary parameter to compare survival distributions between
exposure groups, there are drawbacks to focusing inference on hazard ratios. For instance, the
hazard ratio can be difficult to interpret, especially when trying to summarize the effect of a
treatment or exposure (Hernan, 2010). Presenting estimated survival curves is an alternative
to reporting hazard ratios that may be more interpretable because survival curves summarize
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all information from baseline up to any time t. The IP-weighted approach leads to Kaplan-
Meier type survival curve estimates that are standardized to the entire population under two
different exposures at baseline while accounting for confounding by multiple covariates. A
covariate-adjusted Cox model does not afford such survival curve estimates (Kaufman, 2010;
Xie and Liu, 2005).
Third, the IP-weighted approach with drop out weights requires a weaker assumption
about censoring than the covariate-adjusted Cox model (Hernan et al., 2000; Howe et al.,
2011a; Kalbfleisch and Prentice, 2002). The adjusted Cox model assumes that the censoring
hazard is independent of survival time conditional on being at risk, exposure, and baseline
covariates, whereas the IP-weighted Cox model makes the weaker assumption that censoring
is independent conditional on being at risk, exposure, baseline covariates, and time-varying
covariates (Kalbfleisch and Prentice, 2002; Robins and Finkelstein, 2000). Specifically, if
there are measured time-varying covariates predictive of censoring and survival time, the
IP-weighted approach will yield consistent estimates of the marginal hazard ratio, while the
covariate-adjusted Cox model estimator will not be consistent for the marginal or conditional
hazard ratio (Hernan et al., 2000; Robins et al., 2000; Robins and Finkelstein, 2000).
Results using standardization by IP weights also have, in general, a different interpretation
than results from an unadjusted Cox model. In particular, when exposure is confounded, the
parameter of an unadjusted Cox model is a measure of association and will generally differ
from the parameter of an IP-weighted Cox model (i.e., the marginal hazard ratio), which is a
measure of effect (Robins et al., 2000). On the other hand, when exposure is unconfounded
(e.g., as in randomized trials), the target parameter of both models is the marginal effect. In
this case, drop out weights might still be employed to account for selection bias due to loss to
follow-up (Hernan et al., 2013). Moreover, the use of IP drop out weights yields estimators
that are more efficient (i.e., less variable) than those from an unadjusted Cox model even
when there is no selection bias (Cole and Hernan, 2004; Robins and Finkelstein, 2000).
Estimation of the hazard ratio and survival curves using standardization by IP weights
requires certain assumptions to yield valid inference about the exposure effect. In particular,
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this approach assumes positivity, well-defined exposures, correctly specified models, and no
unmeasured confounding or selection bias. For each level defined by the covariates, positivity
means that there is a positive probability of each level of exposure (Cole and Hernan, 2008).
For example, positivity assumes African American women could possibly have either a history
of IDU or no history of IDU (and similarly for non-African American women). On the
other hand, if African American women could never have a history of IDU, the positivity
assumption would be violated. Well-defined exposures imply that there are not multiple
versions of exposure, or if there are, that they are unimportant (Cole and Frangakis, 2009;
Pearl, 2010; VanderWeele, 2009a). For instance, the duration of exposure to IDU in the
example is assumed to be irrelevant in the sense that an individual’s time until AIDS or death
is assumed to be the same regardless of exposure duration. Alternatively, the marginal effects
being estimated can be viewed as average effects over the distribution of IDU exposure. The
standardized hazard ratio estimator and survival curves require correctly specified IP weights
(i.e., correct covariate functional forms). It is also assumed that sufficient sets of covariates
have been measured to effectively address confounding (i.e., no unmeasured confounding)
(Hernan et al., 2000; Robins et al., 2000) and selection bias due to drop out (Robins and
Finkelstein, 2000). In the example, age, race and nadir CD4 were assumed to be sufficient
to account for confounding and these baseline covariates, time-varying ART initiation, and
exposure were assumed to be sufficient to account for selection bias due to drop out.
Typically, when assessing the effect of a baseline exposure, one would not adjust for
post-baseline covariates in order to avoid potential selection bias (Cole and Hernan, 2002;
Pearl, 2001). For example, post-baseline covariates might be on the causal pathway from the
exposure to the outcome and adjusting for such covariates may lead to attenuated estimates
of the total effect of the exposure (Kalbfleisch and Prentice, 2002). In the example, the
time-varying covariate ART initiation was not included in the covariate-adjusted Cox model.
On the other hand, time-varying ART initiation may be predictive of both drop out and the
survival time, so excluding that variable from the Cox model has the potential to introduce
selection bias. In contrast, the use of IP drop out weights provides a valid approach to
adjusting for a time-varying covariate associated with drop out and survival (Hernan et al.,
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2000, 2001).
We only discussed exposure groups defined at baseline. When interest focuses on expo-
sures that change over time, methods must be adapted accordingly. When a time-varying
covariate is a risk factor for the outcome, predicts later exposure, and is affected by prior
exposure, standard statistical methods (e.g., Cox models with time-varying covariates) are
biased and fail to provide consistent estimators of effects (Hernan et al., 2001; Cole et al.,
2003; Robins, 2000). IP weighting can be used to fit marginal structural Cox models of time-
varying exposures in the presence of such time-varying confounders (Robins et al., 2000). For
example, in HIV-infected individuals, CD4 count is a risk factor for death, predicts subsequent
treatment with ART, and is affected by prior treatment; thus, the marginal structural Cox
model is appropriate for assessing the effect of time-varying ART on overall survival while
adjusting for time-varying CD4 count.
In the illustrative example, we estimated the total effect of IDU history on time to AIDS
or death, which included the indirect effect mediated through ART and the direct effect not
mediated through ART. Estimating the direct and indirect effects of IDU separately may be
of interest and can be obtained by fitting marginal structural models using IP weights as long
as all relevant data is available for these models (VanderWeele, 2009b).
We suggest using expert knowledge to determine which covariates to adjust for prior
to model fitting. Many epidemiologists would retain a possible confounder if its inclusion
changes the estimate of association by more than 10% or 20% and a great deal of precision
is not sacrificed (Mickey and Greenland, 1989). Other approaches for determining which
covariates to adjust for in a model include conditioning on (i) all causes of the exposure
or outcome (VanderWeele and Shpitser, 2011) or (ii) a sufficient set of covariates based on
a causal directed acyclic graph (Greenland et al., 1999a) informed by a priori beliefs or
knowledge (Brookhart et al., 2006). For the weight models, inclusion of covariates that are
unrelated to the exposure but related to the outcome may yield effect estimates with smaller
variance and no increase in bias, so they should be included in the model; however, inclusion
of covariates that are related to the exposure but not to the outcome may lead to effect
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estimates with larger variance and no reduction in bias, so they should be excluded from the
model (Brookhart et al., 2006). Machine learning techniques (Lee et al., 2010, 2011) can be
used as an alternative approach to logistic regression for estimating weights.
Although the IP-weighted method used to analyze the WIHS data attempts to adjust
for confounding and selection bias, the conclusions from the analysis are still subject to the
following considerations. Comparisons of groups from observational studies may be suscep-
tible to unmeasured confounding bias, as the assumption of no unmeasured confounding is
untestable. Similarly, the IP-weighted method assumes drop out is independent of the sur-
vival time conditional on observed baseline and time-varying covariates. The absence of
unmeasured covariates predictive of both censoring and survival times is also an untestable
assumption. Even in the absence of unmeasured covariates, IP drop out weights could fail
to correct for selection bias if there are not a sufficient number of participants during follow-
up (Howe et al., 2011a). The models for the IP weights need to be correctly specified and
sensitivity analysis should be performed to assess robustness of the effect estimates to model
misspecification (Cole and Hernan, 2008). When there are longer follow-up periods (specif-
ically, a large number of participant assessments) or near positivity violations, weights can
become large, leading to imprecise effect estimates. Truncating estimated weights offers some
solution to this problem, although results can be sensitive to choice of truncation cut-off points
(Cole and Hernan, 2008; Kish, 1992). Finally, as with all methods, error in the measurement
of exposure, covariates, or the event status or times could bias the results (Hernan and Cole,
2009).
In conclusion, we have presented an example of survival data pertinent to infectious disease
research and illustrated how to compare groups of study participants using the IP-weighted
Cox proportional hazards model. The methods presented here have broad applicability in
infectious disease research. Careful use of this and other methods for survival analysis will
continue to enrich the evidence base in the field of infectious diseases by providing answers to
questions that are difficult or impossible to answer well without explicitly accounting for time.
Inverse probability weighted Cox models provide a method to estimate covariate-standardized
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hazard ratios and survival curves in observational studies, and obtain information about effects
of treatments or exposures to prevent infectious diseases or their sequela.
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Table 3.1: Characteristics of 1,164 HIV-infected women in the Women’s Interagency HIV
Study December 6, 1995 through December 6, 2005
Characteristicsa History of No History of Overall
Injection Injection
Drug Use Drug Use
(IDU) (IDU)
n = 439 n = 725 n = 1, 164
Age (years) 40 (35, 44) 33 (29, 39) 36 (31, 41)
African American race 273 (62%) 399 (55%) 672 (58%)
Nadir CD4+ count (cells/uL) 352 (208, 522) 348 (216, 505) 349 (213, 517)
Initiated antiretrovirals (ARTs)b 208 (47%) 456 (63%) 664 (57%)
a Median (interquartile range) or number (percent)
b During follow-up
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Table 3.2: Association of history of injection drug use with time to AIDS or death for 1,164
HIV-infected women in the Women’s Interagency HIV Study December 6, 1995 through
December 6, 2005
History of No History of Overall
Injection Injection
Drug Use Drug Use
(IDU) (IDU)
n = 439 n = 725 n = 1, 164
Unadjusted
AIDS cases and deaths 272 (62%) 307 (42%) 579 (50%)
Person-years 2,368 4,721 7,090
Hazard ratio (95% CI) 1.72 (1.46, 2.03) 1 −
10-year risk (95% CI) 0.64 (0.59, 0.68) 0.46 (0.42, 0.49) 0.53 (0.50, 0.56)
10-year risk difference (95% CI) 0.18 (0.13, 0.24) 0 −
Standardizeda
AIDS cases and deaths 248.49 (58%) 308.18 (43%) 556.67 (48%)
Person-years 3,730.97 7,582.69 11,313.66
Hazard ratio (95% CI) 1.53 (1.26, 1.85) 1 −
10-year risk (95% CI) 0.59 (0.54, 0.64) 0.46 (0.42, 0.49) 0.51 (0.47, 0.54)
10-year risk difference (95% CI) 0.14 (0.06, 0.22) 0 −
a IP weighted to account for confounding of exposure due to baseline covariates (age (spline), race, and
nadir CD4 (spline)) and selection bias due to loss to follow-up (covariates included exposure, time-varying
ART initiation, and baseline covariates).
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Table 3.3: Example individual-level estimated exposure weights, drop out weights, and
combined weights for 1,164 HIV-infected women in the Women’s Interagency HIV Study
December 6, 1995 through December 6, 2005
ID Time Time History of Event Drop Exposure Drop Combined
in out Injection out weight out weight
Drug Use weight
(IDU)
34 0.00 0.08 Yes No No 0.499 1.000 0.499
34 0.08 0.17 Yes No No 0.499 1.001 0.499
34 0.17 0.21 Yes No Yes 0.499 1.001 0.500
36 0.00 0.08 No No No 1.135 1.000 1.135
36 0.08 0.17 No No No 1.135 1.001 1.136
36 0.17 0.22 No No Yes 1.135 1.001 1.136
37 0.00 0.08 Yes No No 1.061 1.000 1.061
37 0.08 0.17 Yes No No 1.061 1.000 1.060
37 0.17 0.23 Yes Yes No 1.061 1.000 1.060
38 0.00 0.08 No No No 0.961 1.000 0.961
38 0.08 0.17 No No No 0.961 0.999 0.961
38 0.17 0.25 No No No 0.961 0.999 0.960
38 0.25 0.33 No No No 0.961 0.998 0.959
38 0.33 0.42 No No No 0.961 0.997 0.958
38 0.42 0.43 No Yes No 0.961 0.996 0.957
66 0.00 0.08 Yes No No 0.558 1.000 0.558
66 0.08 0.17 Yes No No 0.558 0.999 0.558
66 0.17 0.25 Yes No No 0.558 0.999 0.558
66 0.25 0.33 Yes No No 0.558 0.998 0.557
66 0.33 0.38 Yes No Yes 0.558 0.998 0.557
34
Figure 3.1: Kaplan-Meier estimated AIDS-free survival curves without accounting for any
covariates (gray curves) and standardized estimated AIDS-free survival curves (accounting
for age, race, nadir CD4, and antiretroviral therapy (ART) initiation) (black curves) for 1,164
HIV-infected women with and without a history of injection drug use (IDU) in the Women’s
Interagency HIV Study December 6, 1995 through December 6, 2005
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Figure 3.2: Estimated log cumulative hazard curves without accounting for any covariates
calculated for 1,164 HIV-infected women with and without a history of injection drug use
(IDU) in the Women’s Interagency HIV Study December 6, 1995 through December 6, 2005
36
Figure 3.3: Standardized estimates of the log cumulative hazard curves (accounting for age,
race, nadir CD4, and antiretroviral therapy (ART) initiation) calculated for 1,164 HIV-
infected women with and without a history of injection drug use (IDU) in the Women’s
Interagency HIV Study December 6, 1995 through December 6, 2005
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CHAPTER 4: GENERALIZING EVIDENCE FROM RANDOMZIED
TRIALS USING INVERSE PROBABILITY OF SAMPLING WEIGHTS
4.1 Introduction
Generalizability is a concern for many studies in public health. Generalizability is defined
as the degree to which an internally valid measure of effect estimated in a sample from one
population would change if the study had been conducted in a different target population. For
example, in trials of treatment for HIV-infected individuals, there is often concern that trial
participants are not representative of the larger population of HIV-positive individuals. One
study highlighted the overrepresentation of African American and Hispanic women among
HIV cases in the U.S. and the limited clinical trial participation of members of these groups
(Greenblatt, 2011). Another study reviewed eligibility criteria of 20 AIDS Clinical Trial Group
(ACTG) studies and found that 28% to 68% of the Women’s Interagency HIV Study (WIHS)
cohort would have been excluded (Gandhi et al., 2005).
There are several quantitative methods that employ sampling scores to assess generaliz-
ability. The sampling score is defined as the probability of participation in the trial conditional
on covariates. These approaches are akin to methods that use treatment propensity scores to
adjust for (measured) confounding (Rubin, 1980) and include the use of inverse probability
of sampling weights and stratification based on sampling scores. In Cole and Stuart (2010),
sampling scores were estimated using logistic regression. An inverse-probability-of-sampling-
weighted Cox proportional hazards model was fit to obtain a hazard ratio and estimated
survival curves. A robust estimate of the variance was employed (Robins, 1998); however, no
closed-form expression for the variance was provided. To date, there is no formal justification
of the large sample statistical properties of these estimators (i.e., statistical consistency and
asymptotic normality). As an alternative, a sampling score stratified estimator was proposed
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to generalize trial results (Tipton, 2013; O’Muircheartaigh and Hedges, 2013; Tipton et al.,
2014).
Following Cole and Stuart (2010) and Stuart et al. (2011), we consider an inverse weighting
approach based on sampling scores to generalize trial effects for continuous outcomes to a
target population and comparisons are made to the stratified estimator. In Section 4.2,
the assumptions and notation for this method are discussed. The inverse probability of
sampling weighted (IPSW) estimator and the stratified estimator are described in Section
4.3. In Section 4.4, large sample properties of the IPSW estimator are derived, including a
closed form expression for the asymptotic variance and a consistent sandwich-type estimator
of the variance. The finite sample performance of the IPSW and stratified estimators are
compared using simulations in Section 4.5. In the Section 4.6, the IPSW estimator is applied
to generalize results from the ACTG to all people currently living with HIV in the U.S.
Section 7 concludes with a discussion.
4.2 Notation and Assumptions
Consider a setting where two data sources are available. A random sample (e.g., cohort
study) of size m is drawn from the near infinite target population and assumed to be rep-
resentative. A second sample of n individuals participate in a randomized trial, and the
treatment assignment mechanism is known to the analyst. The trial is possibly a non-random
(i.e., biased) sample from the near infinite target population. In addition, the treatment effect
(measured as a difference in means) is possibly modified by the same covariates that differ be-
tween the trial and the near infinite target. A covariate is an effect modifier when the average
causal effect of the treatment on the outcome varies across levels of the covariate. In general,
let upper case letters denote random variables and lower case letters denote realizations of
those random variables. Define Z(m+n)×p as a vector of fixed characteristics and assume that
information on Z is available for those in the trial and those in the cohort. Let S = 1 denote
trial participation. For those in the trial, define X as the treatment indicator, where X = 1
if assigned to treatment. Let i = 1, . . . , n+m index the trial and cohort participants.
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Each individual has a vector (Y 0, Y 1) of potential outcomes in the target population.
Y 0 is the value of the response that would have been seen if (possibly contrary to fact) the
participant were randomized to control, and Y 1 is the value of the response that would have
been seen if (possibly contrary to fact) the participant were randomized to treatment. It
is assumed throughout that the stable unit treatment value assumption (SUTVA) (Rubin,
1980; Tipton, 2013) holds, i.e., there are no variations of treatment and there is no interference
between participants. The observed response Y is the response that would have been seen
under the treatment actually assigned in the trial (i.e., one of the two potential outcomes),
defined as Y = Y 1X + Y 0(1 − X). Assume (S,Z) are observed for cohort participants and









expectations are with respect to the potential outcomes in the near infinite target population.
The population average treatment effect (PATE) is ∆ = µ1 − µ0.
Once in the trial, participants are randomly assigned to a treatment group, so that individ-
uals from either group are balanced in that the distribution of Z is the same regardless of treat-
ment assignment conditional on trial participation. This is ignorable treatment assignment
mechanism gained through randomization P (X = x|S = 1,Z, Y 0, Y 1) = P (X = x|S = 1).
Assume an ignorable trial participation mechanism conditional on Z, so P (S = s|Z, Y 0, Y 1) =
P (S = s|Z). In other words, participants in the trial are no different from nonparticipants in
regards to the treatment-outcome relationship conditional on Z. Measurement of all treatment
effect modifiers associated with trial participation will be sufficient to assume an ignorable
trial participation mechanism. Trial participation and treatment positivity are also assumed,
so P (X = x|Z, S = 1) > 0 and P (S = s|Z) > 0 for all Z = z. Assume that participants
in the trial are adherent to their treatment assignment (i.e., ignoring noncompliance issues)
and the model for the sampling scores is correctly specified (i.e., correct covariate functional
forms).
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4.3 Estimators of the Population Average Treatment Effect
A traditional (i.e., unweighted) approach to estimating treatment effects is a difference in














Two estimators that employ sampling scores are considered. In practice, the sampling
scores are likely unknown and can be estimated using a parametric model. Following Cole
and Stuart (2010), the sampling scores P (S = 1|Z = z) are estimated using logistic regression.
Let w(Z,β) = w = P (S = 1|Z), wi = w(Zi,β), and wˆi = w(Zi, βˆ). Let β0 be the vector
of true values of β1×p and βˆ1×p be the vector of estimators of β1×p. To account for the
random sampling of the cohort from the near infinite target population when estimating β ,
each participant in the cohort is inverse weighted by the sampling fraction ri = m/(N − n),
where N is the size of the near infinite target population with N >> n and N >> m. When
estimating β , each trial participant is given a weight of ri = 1.
The IPSW estimator of the PATE is









An alternative approach for estimating the PATE uses stratification based on the sampling
scores (Tipton, 2013; O’Muircheartaigh and Hedges, 2013; Tipton et al., 2014). This estimator
is computed in the following steps. First, β0 is estimated using a (weighted) logistic regression
model and the sampling scores wˆi are computed. These sampling scores are used to form L
strata according to the quintiles of the distribution in the target population. Because we
assume the trial and cohort both arise from the same near infinite target population, the
distribution of sampling scores in the combined trial and cohort are used to estimate the
quintiles (Tipton, 2013). The difference of sample means within each stratum is computed
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among those in the trial. Lastly, the PATE is estimated as a weighted sum of the differences of
sample means across strata, where the weight wˆpl is the proportion of observations in stratum
l in the target population. Let Sil denote trial participation for participant i in stratum l
for i = 1, . . . , (n + m) and l = 1, . . . , L (and Sil = 0 otherwise). Let Xil and Yil denote
treatment assignment and outcome in the trial, respectively, for participant i in stratum l for
i = 1, . . . , (n + m) and l = 1, . . . , L (and Xil = 0, Yil = 0 otherwise). The sampling score













where the L stratum are defined by the distribution of the sampling scores in the near infinite
target population, l = 1, . . . , L and i = 1, . . . , (n+m) and wˆpl = Nl/N with Nl as number in
stratum l in the target and N is the size of the near infinite target.
4.4 Large Sample Properties of the Inverse Probability of Sampling Weighted
Estimator
Let ∆0 be the true value of ∆. Let w0 = w(Zi,β0) be the true weight. Using the fact
that βˆ
p−→ β0 and w(Zi, βˆ) p−→ w(Zi,β0) as n,m → ∞ with n < m and n/(n + m) → c with











p−→ E (Y X/w0)
E (X/w0)
= E (Y |X = 1) = E (Y 1)




p−→ E (Y 0)
Thus, ∆ˆIPW is a consistent estimator of ∆0.
The distribution of Z can differ between the trial and cohort participants. The observed
data (Si,Zi) for i = 1, . . . , n + m is an independent, but not necessarily identically dis-
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tributed sample. We express the IPSW estimator in terms of estimating equations and appeal
to the theory of M-estimation in the Appendix A.6 of Carroll et al. (2010) to demonstrate
that the estimator is asymptotically normal and provide a consistent sandwich-type estima-
tor of the variance (Stefanski and Boos, 2002). The theory of M-estimation implies that
(n+m)1/2(∆ˆIPW −∆0) converges in distribution to N(0,ΣIPW ) (Carroll et al., 2010). Addi-
tionally, the sandwich-type estimator of the variance ΣˆIPW is consistent for ΣIPW , under the
suitable regularity conditions as n,m→∞ with n < m and n/(n+m)→ c with 0 < c ≤ 1.
First, consider the case when β1×p is known, so the solution does not require a score
equation for the sampling score model. Let θˆ
∗
= (µˆ1, µˆ0) and θ
∗














By equation (3) of Stefanski and Boos (2002), since the expectation of ∆ˆIPW is zero at the
true value ∆0, the estimator converges in probability to the true value. Thus, ∆ˆIPW is a con-
sistent estimator of ∆0, which was also demonstrated above. Define the following matrices:











B (θ∗0) = (n + m)−1
∑
iE{cov [Ψ∗∆(Yi,Zi, Xi, Si, θ∗0)]}. θˆ
∗
is asymptotically normally dis-
tributed with mean θ∗0 and covariance matrix Σ∗θ = (n+m)
−1A−1 (θ∗0) B (θ∗0) A−T (θ∗0). When













In the more likely case that β1×p is not known, an additional estimating equation for each
element of β is needed. Using M-estimation, this suggests that the estimating equation based
on the score function of the logistic regression model can be used to obtain the consistent
sandwich-type estimator of the variance (Carroll et al., 2010; Stefanski and Boos, 2002). The
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(Manski and Lerman, 1977; Scott and Wild, 1986, 2002). The estimating equations for µ1,
µ0, and β are
∑
i











Let θˆ = (µˆ1, µˆ0, βˆ) and θ0 = (µ1, µ0,β0). Define the following matrices:









B (θ0) = (n+m)
−1∑
iE{cov [Ψ∆(Yi,Zi, Xi, Si,∆)]}. θˆ is asymptotically normally distributed
with mean θ0 and covariance matrix Σθ = (n+m)
−1A−1 (θ0) B (θ0) A−T (θ0). When β is not








θ − 2× Σ(12)θ
)
(4.3)
By comparison of equations (4.2) and (4.3), it can be shown that the variance is smaller
when the sampling scores are estimated because Σ
(12)
θ is positive definite and larger than
Σ∗(12)θ . This is analogous to a well-known result for inverse probability of treatment weighted
estimators (Hirano et al., 2003; Robins et al., 1992; Wooldridge, 2007). Even if the correct
sampling scores are known, estimation of the sampling scores is preferable due to improved
efficiency. It is common practice to compute the variance using standard software assuming
the weights are known. This leads to valid, but conservative confidence intervals. The consis-
tent sandwich-type estimators of the variance of ∆ˆIPW are provided in Appendix B. In the
Supplemental Materials, an R function is provided to compute the IPSW estimator and its
corresponding sandwich estimator of the variance.
In practice, it is routine to approximate the sampling variance of ∆ˆS by treating the esti-
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mator as the average of L independent, within-stratum, treatment effect estimators (Tipton,
2013; Lunceford and Davidian, 2004). Define the quintiles of wˆi, where the l
th sample quin-
tile is qˆl, l = 1, . . . , L, such that the proportion of wˆi ≤ qˆl is roughly l/L in the near infinite
target. Since we assume the trial and cohort both arise from the same target, the distribu-
tion of sampling scores in the combined trial and target are used to estimate the quintiles
(Tipton, 2013). In practice, the cohort data will need to be weighted to get the correct dis-
tribution of the sampling scores in the target. Let qˆ0 = 0 and qˆL = 1. Define Qˆl = (qˆl−1, qˆl).
Let Nl =
∑N
i=1 I(wˆi ∈ Qˆl) be the number of individuals in stratum l in the target. Let
nl =
∑n+m
i=1 SiI(wˆi ∈ Qˆl) be the number of individuals in stratum l who are selected into the
trial. Let n1l =
∑n+m
i=1 SiXiI(wˆi ∈ Qˆl) be the number of individuals in stratum l who are















i=1 I(wˆi ∈ Qˆl)(XiYi− y¯1l)2, s20l = (nl−n1l)−1
∑n





i=1 I(wˆi ∈ Qˆl)XiYi, and y¯0l = (nl − n1l)−1
∑n
i=1 I(wˆi ∈ Qˆl)(1−Xi)Yi.
4.5 Simulations
Simulations were conducted to compare the performance of the IPSW and stratified es-
timators and included scenarios with a continuous or discrete covariate and a continuous
response. The following quantities were computed in the simulated datasets: the bias for
each estimator, which was the difference between the average of the estimated difference in
means and the true difference in means, standard error, which was the average of the esti-
mated standard errors, Monte Carlo standard error, which was the standard deviation of the
estimated difference in means, and empirical coverage probability, which was the proportion
of times the 95% confidence interval contained the true difference in means.
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A total of 5,000 datasets per scenario were simulated as follows. There were N = 106
observations in the target population and each had (Z1i, wi), where the true sampling score
was wi = {1 + exp(−β0 − β1Z1i)}−1. In the first two scenarios, one binary covariate Z1i ∼
Bern(0.2) was considered and, for scenarios 3 to 6, one continuous covariate Z1i ∼ N(0, 1)
was considered. The covariate Z1i was associated with trial participation and a treatment
effect modifier. A Bernoulli trial participation indicator, Si, was simulated according to the
true sampling score wi in the target population and those with Si = 1 were included the trial.
The parameters β0 and β1 were set to ensure that the probability of sampling into the trial
was a rare event (i.e., the size of the trial was approximately n ≈ 1,000). The cohort was
a random sample of size m = 4,000 from the target population (less those selected into the
trial) and Si was set to zero for those in the cohort. The trial was small compared to the size
of the target, so the cohort was essentially a random sample from the target.
To estimate the weights, the combined trial (Si = 1) and cohort data (Si = 0) was used
to fit a (weighted) logistic regression model with Si as the outcome and the covariate Z1i. To
account for the sampling of the cohort from the target, each participant in the cohort was
inverse weighted by rˆi = m/(N − n). Each trial participant was given a weight of rˆi = 1 in
the logistic model. A weighted score equation for the logistic regression model was included
in the computation of the sandwich estimator of the variance for the IPSW estimator. This
allowed for unbiased estimation of the parameters in the logistic regression model, as well as
the correct information for computation of the variance estimator of ∆ˆIPW .
For the stratified estimator, the distribution of the sampling scores in the target population
was needed. The quintiles and number within each sampling score stratum were obtained
from the inverse weighted data. The approximate estimator of the variance was employed
(i.e., the average variance across sampling score strata).
For those included in the randomized trial (Si = 1), Xi was generated as Bern(0.5) and
the response Y was generated according to Yi = ν0 + ν1Z1i + ξXi +αZ1iXi + i, i ∼ N(0, 1).
For scenarios 1 to 4, (ν0, ν1, ξ, α) = (0, 1, 2, 1). For scenarios 5 to 6, (ν0, ν1, ξ, α) = (0, 1, 2, 2).
Two sampling score models were considered (i.e., weak or moderate Z and S association):
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Scenario 1, 3, and 5 set β = (−7, 0.4); Scenario 2, 4, and 6 set β = (−7, 0.6). The truth was
calculated for each scenario using the distribution of Z in the target population. The truth
was ∆0 = 2.2 for scenarios 1 and 2 and ∆0 = 2 for scenarios 3 through 6.
Comparisons between the IPSW and stratified estimator when the sampling score model is
correctly specified are summarized in Table 4.1. The estimated sampling scores were computed
using logistic regression with the covariate Z1i. The ITT estimator was biased for all scenarios
and had low coverage (results not shown). Depending on the scenario, the size of the trial
ranged from n = 987 to n = 1,091 participants on average over the simulations for each
scenario. For all scenarios, ∆ˆIPW was unbiased. For scenarios 1 to 2, ∆ˆS was unbiased and
standard errors were comparable for the two estimators. For scenarios 3 to 6, ∆ˆS was biased,
possibly due to residual confounding from a continuous covariate in the sampling score model.
For the IPSW estimator, the average of the estimated standard error was approximately
equal to the Monte Carlo standard error, supporting the derivations of the sandwich-type
estimator of the variance. Coverage was around 95% for Wald confidence interval of ∆ˆIPW
for all scenarios. With a continuous covariate, the Wald confidence interval of the stratified
estimator had poor coverage, particularly in the presence of stronger effect modification (i.e.,
scenarios 5 and 6). Upon visual inspection, the IPSW estimator appeared to be normally
distributed (Figure 4.1).
Simulations were also performed with the sampling score model misspecified. A second
covariate was generated for each member of the target population and the true sampling score
was wi = {1 + exp(−β0−β1Z1i−β2Z2i)}−1. For the first two scenarios, Z2i ∼ Bern(0.6), and
for scenarios 3 to 6, Z2i ∼ N(0, 1). For those included in the randomized trial (Si = 1), Xi
was generated as Bern(0.5) and the response Y was generated according to Yi = ν0 + ν1Z1i +
ν2Z2i+ξXi+α1Z1iXi+α2Z2iXi+i, i ∼ N(0, 1). For scenarios 1 to 4, (ν0, ν1, ν2, ξ, α1, α2) =
(0, 1, 1, 2, 1, 1). For scenarios 5 to 6, (ν0, ν1, ν2, ξ, α1, α2) = (0, 1, 1, 2, 2, 2). The estimated
sampling scores were computed using logistic regression with Z1i as the only covaraite. Two
sampling score models were considered (i.e., weak (w) or moderate (m) Z and S association):
Scenario 1, 3, and 5 set β = (−7, 0.4); Scenario 2, 4, and 6 set β = (−7, 0.6). The truth was
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calculated for each scenario using the distribution of Z in the target population. The truth
was ∆0 = 2.8 for scenarios 1 and 2 and ∆0 = 2 for scenarios 3 through 6.
When the sampling score model is misspecified, comparisons between the IPSW and
stratified estimator are summarized in Table 4.2. The bias was reduced by approximately
half when either the IPSW or the stratified estimator was employed, as compared to the
naive within-trial estimator. The empirical sandwich estimator of the variance of the IPSW
estimator performed reasonably well when the sampling score model was misspecified.
4.6 Applications
4.6.1 ACTG 320
The ACTG 320 trial examined the safety and efficacy of adding a protease inhibitor (PI)
to an HIV treatment regimen with two nucleoside analogues. A total of 1,156 participants
were enrolled in ACTG 320 between January 1996 and January 1997 and were recruited
from 33 AIDS clinical trial units and 7 National Hemophilia Foundation sites in the U.S. and
Puerto Rico (Hammer et al., 1997). 200 women were enrolled in ACTG 320 (Hammer et al.,
1997). The baseline characteristics of these women and all participants are shown in Table
4.3 and Table 4.5, respectively.
WIHS and CNICS were considered to be representative samples of their respective target
populations and this analysis only included participants who were HIV-positive, highly active
antiretroviral therapy (HAART) naive, and had CD4 cell counts ≤ 200 cells/mm3 at the
previous visit (m = 493 and m = 6,158, respectively). Lab information (i.e., CD4 cell count)
was carried forward for up to two years. The WIHS is a prospective, observational, multicenter
study of women living with HIV and women at risk for HIV infection in the U.S. (Bacon et al.,
2005). A total of 4,129 women (1,065 HIV-uninfected) were enrolled between October 1994
and December 2012 at six U.S. sites. Of the 493 women included in the WIHS sample, 82%
were non-white, median age was 40 years, and 37% had a history of injection drug use (IDU).
The median CD4 count was 108 cells/mm3. Table 4.3 displays the characteristics of the
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women in the WIHS sample.
The CNICS captures comprehensive and standardized clinical data from point-of-care
electronic medical record systems for population-based HIV research (Kitahata et al., 2008).
CNICS is considered to be representative of all people living with HIV and in clinical care in
the U.S. The CNICS cohort includes over 27,000 HIV-infected adults (at least 18 years of age)
engaged in clinical care since January 1, 1995 at eight CFAR sites in the U.S. Of the 6,158
participants included in the CNICS sample, 80% were male, 60% were non-white, median
age was 41 years, and 20% had a history of IDU. The median CD4 count was 89 cells/mm3.
Table 4.5 displays the characteristics of participants in the CNICS sample.
The IPSW estimator was employed to assess the generalizability of the difference in the
average change in CD4 from baseline to week 4 between treatment groups observed among
women in the ACTG 320 to all women currently living with HIV in the U.S. and among all
participants in the ACTG 320 to all people currently living with HIV in the U.S. Based on
CDC estimates, the size of the first target population was assumed to be 280,000 women and
the size of the second target population was assumed to be 1.1 million people (CDC, 2012).
First, the presence of conditions that could induce a lack of generalizability was assessed in
the datasets. Namely, the variables associated with trial participation that are also treatment
effect modifiers were identified. The distributions of baseline covariates differed between the
women in the trial and WIHS cohort participants (Table 4.3). Age, history of injection drug
use (IDU), race, and CD4 were associated with trial participation (P value < 0.001, P value
= 0.003 and P value < 0.001, and P value = 0.003, respectively). Among women in the
trial, baseline CD4 was associated with the outcome (P value = 0.004), but none of the other
measured covariates were associated with the outcome. There was effect modification on the
difference scale by CD4 at baseline (P value = 0.003), but not by any of the other (measured)
covariates. There were differences in the point estimates of treatment effects across levels of
all four covariates (Table 4.4).
The distributions of all covariates except sex differed between all participants in the trial
and the CNICS cohort participants (Table 4.5). Age, race, and CD4 were associated with
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trial participation (P value < 0.001 for each). In the trial, age, sex and baseline CD4 were
associated with the outcome (P value = 0.04, P value = 0.04 and P value < 0.001, respec-
tively). In the trial, there was effect modification on the difference scale by race and history of
IDU (P value = 0.001 and P value = 0.05, respectively), but not any of the other (measured)
covariates. There were differences in the point estimates of treatment effects across levels of
all five covariates (Table 4.6).
Second, the within-trial treatment effects were computed separately among women only
and all participants. This was an as-treated analysis and ignored treatment compliance issues.
At week 4, women randomized to a regimen with a PI had an average change in CD4 cell
count 24 cells/mm3 higher than women randomized to a regimen without a PI (95% confidence
interval (CI) = (7, 41)). The average change in CD4 cell count was 55 cells/mm3 among those
on a PI, compared to 31 cells/mm3 among those not on a PI. At week 4 among all ACTG
320 participants, those randomized to the regimen with a PI had an average change in CD4
cell count 19 cells/mm3 higher than those randomized to a regimen without a PI (95% CI
= (12, 25)). Those on the regimen with a PI had an average change of 46 cells/mm3, compared
to an average of 27 cells/mm3 among those on the regimen without a PI.
Third, the population average treatment effect was estimated used the IPSW estimator
in equation (4.1). To estimate the sampling scores, the data from the ACTG trial and cohort
(i.e., WIHS or CNICS) were analyzed together, with S = 1 for those in the ACTG trial
and S = 0 for those in the cohort. A logistic regression model was fit on the combined
trial and weighted cohort data. 116 (10%) of trial participants were missing CD4 count at
week 4, so they were excluded. Cohort participants were inverse weighted by the size of the
cohort divided by the size of the target (i.e., rˆi = 493/(280,000−173) for WIHS and rˆi =
6,158/(1,100,000-1,040) for CNICS) and trial participants were given a weight of rˆi = 1. The
outcome was trial participation and the possible covariates were sex, race, age, history of
IDU, and baseline CD4. Variables associated with trial participation, the outcome, or effect
modifiers, as well as all pairwise interactions, were included in the sampling score model. Due
to positivity issues, sex was excluded from the analysis generalizing the ACTG 320 results
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among women to all women living with HIV in the U.S.
Table 4.11 displays the results for ACTG 320 generalized to both target populations.
Among women, there was a significant difference in change in CD4 cell count between the
two treatment groups. At week 4, women randomized to the regimen with a PI had an average
change in CD4 cell count 46 cells/mm3 higher than women randomized to regimen without a
PI (95% CI = (23, 70)). Among all participants, there was a significant difference in average
change in CD4 cell count between the two treatment groups. At week 4, those randomized
to a regimen with a PI had a change in an average CD4 cell count 17 cells/mm3 higher than
those randomized to a regimen without a PI (95% CI = (9, 25)).
4.6.2 ACTG A5202
The ACTG A5202 trial examined equivalence of abacavir-lamivudine (ABC-3TC) or
tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) plus efavirenz or ritonavir-boosted
atazanavir. A total of 1,857 participants were enrolled in ACTG A5202 between September
2005 and November 2007 and were recruited from 59 ACTG sites in the U.S. and Puerto Rico
(Sax et al., 2009, 2011). 322 women were enrolled in ACTG A5202 (Sax et al., 2009, 2011).
The baseline characteristics are shown in Table 4.7 among women and in Table 4.9 among all
participants.
WIHS and CNICS were considered to be representative samples of their respective target
populations and this analysis only included participants who were HIV-positive, antiretroviral
(ART) naive, and had viral load > 1,000 copies/ml at the previous visit (m = 1,012 and m =
12,302, respectively). Lab information was carried forward for up to two years (i.e., CD4 and
viral load). Of the 1, 012 women included in the WIHS sample, 83% were non-white, median
age was 39 years, 38% had a history of IDU, 35% had hepatitis B/C, and 37% had an AIDS
diagnosis. The median CD4 count was 290 cells/mm3 and the median log10 viral load was
4.61 copies/ml. Table 4.7 displays the characteristics of the women in the WIHS sample. Of
the 12,302 participants included in the CNICS sample, 82% were male, 55% were non-white,
median age was 39 years, 17% had a history of IDU, 18% had hepatitis B/C, and 23% had
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an AIDS diagnosis. The median CD4 count was 271 cells/mm3 and the median log10 viral
load was 4.64 copies/ml. Table 4.9 displays the characteristics of participants in the CNICS
sample.
The IPSW estimator was employed to assess the generalizability of the difference in the
average change in CD4 from baseline to week 48 between treatment groups observed among
women in ACTG A5202 to all women currently living with HIV in the U.S. and among all
participants in the ACTG A5202 to all people currently living with HIV in the U.S. Based on
CDC estimates, the size of the first target population was assumed to be 280,000 women and
the size of the second target population was assumed to be 1.1 million people (CDC, 2012).
Because randomization was the same for both stratum, the screening viral load strata were
ignored in the illustrative example. Only blinded follow-up was included in the analysis.
First, the presence of conditions that could induce a lack of generalizability was assessed in
the datasets. Namely, the variables associated with trial participation that are also treatment
effect modifiers were identified. The distributions of baseline CD4, history of IDU, hepatitis
B/C, and AIDS diagnosis differed between the trial and WIHS cohort participants (Table 4.7).
Age, AIDS diagnosis, history of IDU, baseline CD4, hepatitis, and viral load were associated
with trial participation (P value < 0.001, P value < 0.001, P value < 0.001, P value < 0.001,
P value = 0.003, and P value < 0.001, respectively). Age (P value = 0.02) and CD4 (P value
= 0.01) were associated with the outcome. There was effect modification on the difference
scale by age (P value = 0.02), history of IDU (P value = 0.03), and hepatitis B/C (P value
= 0.04). There were differences in the point estimates of treatment effects across levels of all
covariates (Table 4.8).
The distributions of baseline CD4, history of IDU, hepatitis, and AIDS diagnosis differed
between the trial and CNICS cohort participants (Table 4.9). Race, AIDS diagnosis, hepatitis
B/C, history of IDU, CD4, and log viral load were associated with trial participation (P value
< 0.001 for each variable). Age, hepatitis B/C, viral load, and CD4 were associated with the
outcome (P value < 0.001, P value < 0.001, P value < 0.001, and P value = 0.03, respectively).
There was effect modification on the difference scale by history of IDU and baseline CD4 (P
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value = 0.007 and P value = 0.05, respectively). There were differences in the point estimates
of treatment effects across levels of all covariates, except AIDS diagnosis (Table 4.10).
Second, the within-trial treatment effects were computed separately among women only
and all participants. This was an as-treated analysis and ignored treatment compliance issues.
Among the 322 women in A5202 at week 48, those randomized to ABC-3TC had an average
change in CD4 cell count 1 cell/mm3 higher than those randomized to a regimen with TDF-
FTC (95% CI = (−35, 37)). The average change in CD4 cell count was 194 cells/mm3 among
those on ABC-3TC, compared to 193 cells/mm3 among those on TDF-FTC. Among the
1,857 participants in A5202, those randomized to ABC-3TC had an average change in CD4
cell count 6 cells/mm3 higher than those randomized to a regimen with TDF-FTC (95%
CI = (−8, 20)). The average change in CD4 cell count was 193 cells/mm3 among those on
ABC-3TC, compared to 187 cells/mm3 among those on TDF-FTC.
Third, the population average treatment effect was estimated used the IPSW estimator
in equation (4.1). To estimate the sampling scores, the data from the ACTG trial and cohort
(i.e., WIHS or CNICS) were analyzed together, with S = 1 for those in the ACTG trial
and S = 0 for those in the cohort. A logistic regression model was fit on the combined
trial and weighted cohort data. 417 (22%) of trial participants were missing CD4 count at
week 48, so they were excluded. Cohort participants were inverse weighted by the size of the
cohort divided by the size of the target (i.e., rˆi = 1,012/(280,000-255) for WIHS and rˆi =
12,302/(1,100,000-1,440) for CNICS) and trial participants were given a weight of rˆi = 1.
The outcome was trial participation and the possible covariates were sex, race, age, history
of IDU, hepatitis B/C, AIDS diagnosis, baseline CD4 and baseline log10 viral load. Variables
associated with trial participation, the outcome, or effect modifiers, as well as all pairwise
interactions, were included in the sampling score model. Because hepatitis B/C and history of
IDU were correlated (r = 0.69), history of IDU was excluded from the sampling score model.
Due to positivity issues, sex was excluded from the analysis generalizing the ACTG A5202
results among women to all women living with HIV in the U.S.
Table 4.11 displays the results for ACTG A5202 generalized separately to both target
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populations. Among women, the differences in the average change in CD4 cell count at week
48 between the regimens was computed. Women randomized to ABC-3TC had an average
change in CD4 cell count 35 cells/mm3 higher than women randomized to TDF-FTC (95%
CI = (−45, 115)). Among all participants, the differences in the average change in CD4 cell
count at week 48 between the regimens was computed. Those randomized to ABC-3TC had
an average change in CD4 cell count 2 cells/mm3 lower than those randomized to TDF-FTC
(95% CI = (−31, 28)).
4.7 Discussion
Following Cole and Stuart (2010) and Stuart et al. (2011), we considered an estimator
using inverse probability of sampling weights to generalize results from a randomized trial
to a specific target population. The IPSW estimator compares the outcome in the target
population if (possibly contrary to fact) everyone had been randomized to treatment with the
outcome in the target population if (possibly contrary to fact) everyone had been randomized
to control. The IPSW estimator was shown to be consistent and asymptotically normal and a
consistent sandwich-type estimator of the variance was provided. In the following, we discuss
some recent work addressing generalizability and explore caveats of this approach.
In the illustrative example, the IPSW estimator was employed to generalize results from
the ACTG to all people currently living with HIV in the U.S. For ACTG 320, the effect
estimated with the ITT was comparable to the effect estimated with the IPSW, so the results
appear to be generalizable to all people living with HIV in the U.S. For the A5202 results
among women, the difference in the effect estimates is primarily due to hepatitis, which was
associated with participation in the trial and a treatment effect modifier. Results were not
sensitive to the specification of the size of the target population; however, some results were
sensitive to the specification of the sampling score model.
In a previous paper by Cole and Stuart (2010), the ACTG 320 results were generalized to a
target population of all people infected with HIV in the U.S. Consistency and asymptotic nor-
mality of the proposed estimator were not formally shown. The results herein complete that
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effort. In Cole and Stuart (2010), information on the target was obtained using survey data
(i.e., CDC estimates). The approach presented in herein uses richer data from representative
cohorts.
When applying this method, the analysis is subject to the following considerations. The
absence of unmeasured covariates associated with the trial participation mechanism and treat-
ment effect modifiers is an untestable assumption. Treatment compliance issues were ignored
in this method; however, this issue should be considered in analyses. The sampling score
model was assumed to be correct (i.e., correct covariate functional forms); however, this is
not guaranteed in practice. The stratified estimator (Tipton et al., 2014; O’Muircheartaigh
and Hedges, 2013) requires that individuals sharing the same sampling score can be identi-
fied, which may be difficult in practice. This estimator may be biased when there is residual
confounding within strata and, therefore, is not a consistent estimator of the PATE in some
cases (e.g., a continuous covariate in the sampling score model) (Lunceford and Davidian,
2004).
Weighted logistic regression was used as an approach to consistently estimate the param-
eters of the logistic regression model (e.g., the intercept); however, other approaches may be
possible. Additional research to develop an augmented estimator could improve efficiency
(Zhang et al., 2008). This method could be extended to accommodate the presence of in-
terference. This method could also incorporate information on the target obtained through
a nonrepresentative sample. Lastly, this method holds for continuous and binary outcomes.
Further results are needed for estimation with right-censored data.
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Table 4.1: Summary of Monte Carlo results for estimators of the population average treat-
ment effect when the sampling score model was correctly specified with a continuous out-
come for 5,000 samples with m = 4,000 and n ≈ 1,000. Scenarios are described in the text.
∆0 = 2.2 for scenarios 1 and 2 and ∆0 = 2.0 for scenarios 3 to 6 (ITT = intention-to-
treat; S = stratified; IPSW = inverse probability of sampling weighted; ESE = Empirical
standard error (×100); ASE = Average standard error (×100); ECP = Empirical coverage
probability)
Bias ESE ASE ECP
Scenario Cov. (β1,α) ∆ˆITT ∆ˆS ∆ˆIPSW ∆ˆS ∆ˆIPSW ∆ˆS ∆ˆIPSW ∆ˆS ∆ˆIPSW
1 Bin. (0.4,1) 0.07 2e-3 2e-3 6.2 7.1 7.1 7.3 0.98 0.95
2 Bin. (0.6,1) 0.11 -3e-5 -6e-4 6.3 7.1 6.6 7.1 0.96 0.95
3 Cont. (0.4,1) 0.20 0.04 1e-3 8.1 13.4 7.9 13.4 0.91 0.95
4 Cont. (0.6,1) 0.60 0.07 -1e-3 8.6 15.0 8.6 14.9 0.88 0.95
5 Cont. (0.4,2) 0.80 0.09 3e-3 9.4 17.2 8.9 17.2 0.81 0.95
6 Cont. (0.6,2) 1.20 0.14 -1e-3 10.1 19.9 9.8 19.6 0.70 0.95
Table 4.2: Summary of Monte Carlo results for estimators of the population average treat-
ment effect when the sampling score model was misspecified with a continuous outcome for
5,000 samples with m = 4,000 and n ≈ 1,000. Scenarios are described in the text. ∆0 = 2.8
for scenarios 1 and 2 and ∆0 = 2.0 for scenarios 3 to 6 (ITT = intention-to-treat; S = strat-
ified; IPSW = inverse probability of sampling weighted; ESE = Empirical standard error
(×100); ASE = Average standard error (×100); ECP = Empirical coverage probability)
Bias ESE ASE ECP
Scenario Cov. (β1,α) ∆ˆITT ∆ˆS ∆ˆIPSW ∆ˆS ∆ˆIPSW ∆ˆS ∆ˆIPSW ∆ˆS ∆ˆIPSW
1 Bin. (0.4,1) 0.16 0.09 0.09 7.03 7.67 7.73 7.61 0.80 0.77
2 Bin. (0.6,1) 0.24 0.13 0.13 6.36 6.82 6.62 6.86 0.49 0.52
3 Cont. (0.4,1) 0.80 0.45 0.40 13.12 16.53 12.88 16.57 0.07 0.32
4 Cont. (0.6,1) 1.20 0.67 0.60 13.19 17.58 12.90 17.24 <0.01 0.08
5 Cont. (0.4,2) 1.60 0.89 0.80 17.37 22.12 16.98 22.20 <0.01 0.05
6 Cont. (0.6,2) 2.39 1.34 1.20 17.49 23.79 17.04 23.32 <0.01 <0.01
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Table 4.3: Characteristics of 493 women in the Women’s Interagency HIV Study (WIHS)
who were HIV-positive, HAART naive, and had CD4 cell count ≤ 200 cells/mm3 at the
previous visit and 200 women at baseline in AIDS Clinical Trials Group (ACTG) 320 by
treatment group (with and without a protease inhibitor (PI))
WIHS ACTG 320 ACTG 320 ACTG 320
Protease No Protease
Inhibitor (PI) Inhibitor (PI)
Variable (m = 493) (n = 200) (n1 = 106) (n0 = 94)
Race or ethnic group - no. (%)
White, non-Hispanic 87 (18) 61 (31) 26 (25) 35 (37)
Black, non-Hispanic 272 (55) 95 (48) 54 (51) 41 (44)
Hispanic 124 (25) 42 (21) 25 (24) 17 (18)
Asian/Other 10 (2) 2 (1) 1 (1) 1 (1)
Median age - yr (Q1-Q3) 40 (35-45) 36 (30-42) 37 (31-42) 36 (30-43)
Age group - no. (%)
16-<30 yr 35 (7) 46 (23) 22 (21) 24 (26)
30-<40 yr 211 (43) 88 (44) 48 (45) 40 (43)
40-<50 yr 196 (40) 53 (27) 27 (26) 26 (28)
≥50 yr 51 (10) 13 (7) 9 (9) 4 (4)
Injection drug use - no. (%) 180 (37) 36 (18) 24 (23) 12 (13)
Median CD4 count (Q1-Q3) 108 (41-172) 82 (26-139) 93 (29-139) 70 (23-138)
Baseline CD4 count - no. (%)
<50 cells/mm3 148 (30) 72 (36) 35 (33) 37 (39)
50-<100 cells/mm3 83 (17) 43 (22) 22 (21) 21 (22)
100-<200 cells/mm3 182 (37) 73 (37) 44 (42) 29 (31)
≥200 cells/mm3 80 (16) 12 (6) 5 (5) 7 (7)
Table 4.4: Difference in the average change in CD4 from baseline to week 4 between treat-
ment groups (protease inhibitor (PI) vs. no PI) for each level of the covariates among 173
women in AIDS Clinical Trials Group 320 with a corresponding 95% confidence interval
(CI)
Variable Difference
in Change in CD4
at Week 4
Mean (95 % CI)
Race or ethnic group
White, non-Hispanic 21 (-11, 53)
Black, non-Hispanic 19 (-8, 45)
Hispanic/Asian/Other 35 (-2, 72)
Age group
18-<30 yr -3 (-47, 41)
30-<40 yr 33 (7, 57)
40-<50 yr 26 (-7, 60)
≥50 yr 16 (-43, 75)
Injection drug use
Yes 43 (-5, 90)
No 23 (4, 42)
Baseline CD4 count
<50 cells/mm3 14 (-13, 41)
50-<100 cells/mm3 57 (22, 92)
≥100 cells/mm3 14 (-14, 41)
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Table 4.5: Characteristics of 6,158 participants in the CFAR Network of Integrated Clinical
Systems (CNICS) who were HIV-positive, HAART naive, and had CD4 cell count ≤ 200
cells/mm3 at the previous visit and 1,156 participants at baseline in AIDS Clinical Trials
Group (ACTG) 320 by treatment group (with and without a protease inhibitor (PI))
CNICS ACTG 320 ACTG 320 ACTG 320
Protease No Protease
Inhibitor (PI) Inhibitor (PI)
Variable (m = 6,158) (n = 1,156) (n1 = 577) (n0 = 579)
Male sex - no. (%) 4,909 (80) 956 (83) 471 (82) 485 (84)
Race or ethnic group - no. (%)a
White, non-Hispanic 2,436 (40) 598 (52) 303 (53) 295 (51)
Black, non-Hispanic 2,690 (44) 328 (28) 163 (28) 165 (29)
Hispanic 734 (12) 205 (18) 99 (17) 106 (18)
Asian/Other 298 (5) 25 (2) 12 (2) 13 (2)
Median age - yr (Q1-Q3) 41 (34-47) 38 (33-44) 38 (33-44) 38 (33-44)
Age group - no. (%)
16-<30 yr 714 (12) 142 (12) 69 (12) 73 (13)
30-<40 yr 2,108 (34) 536 (47) 272 (47) 264 (46)
40-<50 yr 2,315 (38) 350 (30) 169 (29) 181 (31)
≥50 yr 1,021 (17) 128 (11) 67 (12) 61 (11)
Injection drug use - no. (%) 1,241 (20) 184 (16) 91 (16) 93 (16)
Median CD4 count (Q1-Q3) 89 (27-172) 75 (23-137) 80 (24-138) 70 (23-135)
Baseline CD4 count - no. (%)
<50 cells/mm3 2,237 (36) 453 (39) 219 (38) 234 (41)
50-<100 cells/mm3 1,047 (17) 248 (22) 118 (20) 130 (23)
100-<200 cells/mm3 1,818 (30) 372 (32) 200 (35) 172 (30)
≥200 cells/mm3 1,056 (17) 82 (7) 40 (7) 42 (7)
aOne A5202 participant missing baseline CD4 cell count.
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Table 4.6: Difference in the average change in CD4 from baseline to week 4 between treat-
ment groups (protease inhibitor (PI) vs. no PI) for each level of the covariates among
1,040 participants in AIDS Clinical Trials Group (ACTG) 320 with a corresponding 95%
confidence interval (CI)
Variable Difference
in Change in CD4
at Week 4
Mean (95 % CI)
Sex
Male 17 (10, 25)
Female 24 (8, 40)
Race or ethnic group
White, non-Hispanic 14 (4, 23)
Black, non-Hispanic 11 (-2, 23)
Hispanic 48 (32, 64)
Asian/Other 9 (-35, 53)
Age group
18-<30 yr 14 (-9, 37)
30-<40 yr 23 (13, 33)
40-<50 yr 13 (2, 25)
≥50 yr 20 (1, 38)
Injection drug use
Yes 3 (-14, 20)
No 21 (14, 29)
Baseline CD4 count
<50 cells/mm3 24 (14, 35)
50-<100 cells/mm3 26 (12, 41)
100-<200 cells/mm3 9 (-3, 21)
≥200 cells/mm3 -3 (-29, 23)
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Table 4.7: Characteristics of 1,012 women in the Women’s Interagency HIV Study (WIHS)
who were HIV-positive, ART naive, and had viral load> 1000 copies/ml at the previous visit
and 322 women at baseline in AIDS Clinical Trials Group (ACTG) A5202 by treatment
group (abacavir-lamivudine (ABC-3TC) vs. tenofovir disoproxil fumarate-emtricitabine
(TDF-FTC))
WIHS ACTG A5202 ACTG A5202 ACTG A5202
ABC-3TC TDF FTC
Variable (m = 1,012) (n = 322) (n1 = 173) (n0 = 149)
Race or ethnic group - no. (%)
White, non-Hispanic 171 (17) 57 (18) 30 (17) 27 (18)
Black, non-Hispanic 586 (58) 172 (53) 94 (54) 78 (52)
Hispanic 222 (22) 82 (26) 42 (24) 40 (27)
Asian/Other 33 (3) 11 (3) 7 (4) 4 (3)
Median age - yr (Q1-Q3) 39 (33-44) 39 (31-46) 39 (31-46) 39 (31-46)
Age group - no. (%)
16-<30 yr 123 (12) 57 (18) 30 (17) 27 (18)
30-<40 yr 435 (43) 110 (34) 62 (36) 48 (32)
40-<50 yr 345 (34) 107 (33) 54 (31) 53 (36)
≥50 yr 109 (11) 48 (15) 27 (16) 21 (14)
Injection drug use - no. (%) 388 (38) 18 (6) 9 (5) 9 (6)
Hepatitis B/C - no. (%) 356 (35) 25 (8) 14 (8) 11 (7)
AIDS diagnosis - no. (%) 373 (37) 62 (19) 39 (23) 23 (15)
CD4 count - no. (%)
<50 cells/mm3 102 (10) 61 (19) 38 (22) 23 (15)
50-<100 cells/mm3 61 (6) 24 (7) 15 (9) 9 (6)
100-<200 cells/mm3 162 (16) 55 (17) 28 (16) 27 (18)
200-<350 cells/mm3 295 (29) 130 (40) 65 (38) 65 (44)
≥350 cells/mm3 392 (39) 52 (16) 27 (16) 25 (17)
Median CD4 count (Q1-Q3) 290 (162-423) 226 (87-313) 209 (60-308) 249 (129-316)
Viral load - no. (%)
<50,000 cp/ml 552 (55) 187 (58) 93 (54) 94 (63)
50,000-<100,000 cp/ml 144 (14) 62 (19) 33 (19) 29 (20)
100,000-<300,000 cp/ml 193 (19) 38 (12) 24 (14) 14 (9)
300,000-<500,000 cp/ml 55 (5) 9 (3) 6 (3) 3 (2)
≥500,000 cp/ml 68 (7) 26 (8) 17 (10) 9 (6)
Median log10 viral load (Q1-Q3) 4.61 (4.04-5.11) 4.58 (4.07-4.93) 4.62 (4.10-5.09) 4.55 (4.04-4.86)
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Table 4.8: Difference in the average change in CD4 from baseline to week 48 between
treatment groups (abacavir-lamivudine (ABC-3TC) vs. tenofovir disoproxil fumarate-
emtricitabine (TDF-FTC)) for each level of the covariates among 255 women in AIDS
Clinical Trials Group (ACTG) A5202 with a corresponding 95% confidence interval (CI)
Variable Difference in the Average
Change in CD4 at Week 48
Mean (95% CI)
Race or ethnic group
White, non-Hispanic -58 (-144, 28)
Black, non-Hispanic 21 (-27, 70)
Hispanic 18 (-55, 91)
Asian/Other -90 (-301, 120)
Age group
18-<30 yr 108 (24, 191)
30-<40 yr -20 (-80, 40)
40-<50 yr -39 (-102, 24)
≥50 yr -15 (-110, 79)
Injection drug use
Yes -7 (-44, 30)
No -103 (-202, -5)
Hepatitis B/C
Yes 130 (4, 257)
No -10 (-48, 27)
AIDS diagnosis
Yes -27 (-116, 62)
No 5 (-35, 45)
CD4 count
<50 cells/mm3 -13 (-103, 77)
50-<100 cells/mm3 49 (-94, 192)
100-<200 cells/mm3 2 (-87, 90)
200-<350 cells/mm3 34 (-21, 89)
≥350 cells/mm3 -83 (-168, 3)
Viral load
<50,000 cp/ml -1 (-46, 45)
50,000-<100,000 cp/ml -16 (-99, 68)
100,000-<300,000 cp/ml 57 (-56, 171)
300,000-<500,000 cp/ml -48 (-312, 216)
≥500,000 cp/ml -40 (-196, 116)
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Table 4.9: Characteristics of 12,302 participants in the CFAR Network of Integrated Clin-
ical Systems (CNICS) who were HIV-positive, ART naive, and had viral load > 1000
copies/ml at the previous visit and 1,857 participants at baseline in AIDS Clinical Trials
Group (ACTG) A5202 by treatment group (abacavir-lamivudine (ABC-3TC) vs. tenofovir
disoproxil fumarate-emtricitabine (TDF-FTC))
CNICS ACTG A5202 ACTG A5202 ACTG A5202
ABC-3TC TDF FTC
Variable (m = 12,302) (n =1,857) (n1 = 928) (n0 = 929)
Male sex - no. (%) 10,063 (82) 1,535 (83) 755 (81) 780 (84)
Race or ethnic groupa - no. (%)
White, non-Hispanic 5,567 (45) 746 (46) 363 (39) 383 (41)
Black, non-Hispanic 4,682 (38) 615 (33) 317 (34) 298 (32)
Hispanic 1,420 (12) 429 (23) 214 (23) 215 (23)
Asian/Other 633 (5) 62 (3) 31 (3) 31 (3)
Median age - yr (Q1-Q3) 39 (31-46) 38 (31-45) 38 (30-45) 39 (31-45)
Age group - no. (%)
16-<30 yr 2,454 (20) 404 (22) 201 (22) 203 (22)
30-<40 yr 4,225 (34) 625 (34) 335 (36) 290 (31)
40-<50 yr 3,896 (32) 573 (31) 273 (29) 300 (32)
≥50 yr 1,727 (14) 255 (14) 119 (13) 136 (15)
Injection drug use - no. (%) 2,042 (17) 162 (9) 77 (8) 85 (9)
Hepatitis B/C - no. (%) 2,245 (18) 165 (9) 75 (8) 90 (10)
AIDS diagnosis - no. (%) 2,834 (23) 312 (17) 172 (19) 140 (15)
CD4 countb - no. (%)
<50 cells/mm3 2,000 (16) 339 (18) 176 (19) 163 (18)
50-<100 cells/mm3 920 (7) 150 (8) 74 (8) 76 (8)
100-<200 cells/mm3 1,692 (14) 311 (17) 159 (17) 152 (16)
200-<350 cells/mm3 3,262 (27) 656 (35) 312 (34) 344 (37)
≥350 cells/mm3 4,428 (36) 400 (22) 207 (22) 193 (21)
Median CD4 count (Q1-Q3) 271 (109-427) 230 (90-334) 229 (84-338) 230 (96-330)
Viral load - no. (%)
<50,000 cp/ml 6,450 (52) 1,000 (54) 492 (53) 508 (55)
50,000-<100,000 cp/ml 1,861 (15) 391 (21) 196 (21) 195 (21)
100,000-<300,000 cp/ml 2,232 (18) 203 (11) 106 (11) 97 (10)
300,000-<500,000 cp/ml 744 (6) 72 (4) 38 (4) 34 (4)
≥500,000 cp/ml 1,015 (8) 191 (10) 96 (10) 95 (10)
Median log10 viral load (Q1-Q3) 4.64 (3.95-5.18) 4.66 (4.33-5.01) 4.66 (4.31-5.06) 4.65 (4.34-4.96)
aFive A5202 participants were missing race.
bOne A5202 participant was missing CD4 cell count.
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Table 4.10: Difference in the average change in CD4 from baseline to week 48 between
treatment groups (abacavir-lamivudine (ABC-3TC) vs. tenofovir disoproxil fumarate-
emtricitabine (TDF-FTC)) for each level of the covariates among 1,440 participants in
ACTG A5202 with a corresponding 95% confidence interval (CI)
Variable Difference in the Average
Change in CD4 at Week 48
Mean (95% CI)
Sex
Male 22 (-5, 48)
Female 3 (-13, 18)
Race or ethnic group
White, non-Hispanic -4 (-27, 18)
Black, non-Hispanic 14 (-11, 39)
Hispanic 11 (-19, 41)
Asian/Other 19 (-56, 94)
Age group
18-<30 yr 10 (-22, 41)
30-<40 yr 5 (-20, 29)
40-<50 yr 10 (-15, 36)
≥50 yr -13 (-51, 26)
Injection drug use
Yes -0.03 (-15, 15)
No -38 (-72, -3)
Hepatitis B/C
Yes 49 (1, 99)
No 1 (-14, 16)
AIDS diagnosis
Yes 6 (-31, 43)
No 5 (-11, 21)
CD4 count
<50 cells/mm3 14 (-21, 51)
50-<100 cells/mm3 8 (-44, 60)
100-<200 cells/mm3 13 (-22, 49)
200-<350 cells/mm3 16 (-8, 39)
≥350 cells/mm3 -21 (-51, 8)
Viral load
<50,000 cp/ml -3 (-21, 15)
50,000-<100,000 cp/ml 38 (7, 69)
100,000-<300,000 cp/ml 20 (-27, 68)
300,000-<500,000 cp/ml -46 (-125, 32)
≥500,000 cp/ml -24 (-74, 26)
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Table 4.11: Results for continuous outcomes in two AIDS Clinical Trials Group (ACTG)
trials where the sampling score model included all variables associated with trial partici-
pation, the outcome, or effect modifiers (with a linear term for continuous variables) and
all pairwise interactions (ITT = intention-to-treat; IPSW = inverse probability of sampling
weighted; S = stratified). Difference in means with a 95% confidence interval displayed
below.
Cohort Trial ∆ˆITT ∆ˆIPSW ∆ˆS
WIHS 320a 24 (7, 41) 46 (23, 70) 38 (17, 59)
WIHS A5202b 1 (-35, 37) 35 (-45, 115) -19 (-62, 25)
CNICS 320 19 (12, 25) 17 (9, 25) 18 (9, 26)
CNICS A5202 6 (-8, 20) -2 (-31, 28) 7 (-18, 32)
aFor ACTG 320, the treatment contrast was PI vs. no PI.
bFor A5202, the treatment contrast was ABC-3TC vs. TDF-FTC.
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 Intention−to−Treat
1.0 1.5 2.0 2.5 3.0
 
Stratified
1.0 1.5 2.0 2.5 3.0
 
IP weighted
1.0 1.5 2.0 2.5 3.0
Figure 4.1: Comparison of the distributions of intention-to-treat estimator ∆ˆITT , inverse
probability of sampling weighted estimator ∆ˆIPSW , and stratified estimator ∆ˆS based on
5,000 simulated datasets where the sampling score model is correctly specified and ∆0 = 2.0
with one continuous covariate, β = (−7, 0.6), and α = 1
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CHAPTER 5: GENEARLIZING TRIAL RESULTS FOR
RIGHT-CENSORED DATA USING INVERSE PROBABILITY OF
SAMPLING WEIGHTS
5.1 Introduction
Time-to-event endpoints are often of interest in clinical trials. Kaplan-Meier estimators are used to
quantify survival distributions and are a commonly used nonparametric estimator in survival analysis
(Kalbfleisch and Prentice, 2002). If the trial is random sample from the target population, standard
methods, such as the Kaplan-Meier estimator, are appropriate and comparisons between groups can be
made with a log rank test. However, when the trial participation mechanism is possibly non-random
sample, properly weighting the observed trial data to estimate the survival distribution in the target
population may be necessary.
The Kaplan-Meier estimator is also appealing because it does not require a proportional hazards
assumption or possible complications faced by hazard ratios estimated using a Cox proportional haz-
ards model. Presenting estimated survival curves is an alternative to reporting hazard ratios that
may be more interpretable because survival curves summarize all information from baseline up to any
time t (Cole and Hernan, 2004; Hernan, 2010). Robins and Finkelstein (2000) proposed an adjusted
Kaplan-Meier estimator using inverse probability (IP) of censoring weights to estimate effects in the
presence of selection bias using randomized trial data. Xie and Liu (2005) developed an adjusted
Kaplan-Meier estimator using inverse probability (IP) of treatment weights to estimate effects in the
presence of confounding using observational data. They presented estimators for the marginal survival
curves, including the development of a weighted log rank test.
Cole and Stuart (2010) proposed a method for generalizing trial results to a target population for
right-censored data using an IP-weighted Cox model with sampling weights. A robust estimator of the
variance of the hazard ratio was employed (Lin and Wei, 1989). The authors provided an expression
for the bias of the intention-to-treat estimator when the parameter of interest is a difference in means
in the target and a proof that an inverse probability weighted estimator is unbiased for the mean of the
potential outcomes in the target population; however, the performance of the bootstrap standard error
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was not evaluated. The authors demonstrated this method by generalizing results from the acquired
immunodeficiency syndrome (AIDS) Clinical Trials Group (ACTG) to all people currently living with
human immunodeficiency virus (HIV) in the U.S.
Following Cole and Stuart (2010) and Buchanan et al. (In preparation), an inverse probability of
sampling weighted (IPSW) estimator is considered for right-censored data using a weighted Kaplan-
Meier (KM) estimator and comparisons are made to a proposed stratified estimator. The outline of the
remainder of this paper is as follows. In Section 5.2, the assumptions and notation for this method are
discussed. Expressions for the IPSW estimator and the stratified estimator are provided in Section 5.3.
The large sample performance of the IPSW and stratified estimators are compared using simulations
in Section 5.4. In the penultimate section, the IPSW estimator is applied to generalize results from
two ACTG trials to all people currently living with HIV in the U.S. Related work and caveats of this
method are discussed in the last section.
5.2 Assumptions and Notation
Consider a setting where two data sources are available. A random sample (e.g., cohort study) of
size m is drawn from the near infinite target population and assumed to be representative. A second
sample of n individuals participate in a randomized trial, and the treatment assignment mechanism
is known to the analyst. The trial is possibly a non-random (i.e., biased) sample from the near
infinite target population. In addition, the treatment effect is possibly modified by the same covariates
that differ between the trial and the near infinite target. Note that the population may remain
unenumerated. Define Z(n+m)×p as a vector of fixed characteristics and assume that information on
Z is available for those in the trial and cohort. Let S = 1 denote trial participation. For those in
the trial, define X as the treatment indicator, where X = 1 if assigned to treatment. Let (T,C, δ,X)
denote the right-censored trial data, where T is the event time, C is the censoring time, and δ is the
event indicator with δ = 0 if T > C (and δ = 1 if T ≤ C). Define T ∗ = min(T,C) as the observed
time in the trial. Let i = 1, . . . , n+m index trial and cohort participants.
Define T 1 as the event time that would have been seen if (possibly contrary to fact) the participant
were to receive treatment at the time of randomization (i.e., t = 0) (and followed until they experienced
the event) and T 0 as the event time that would have been seen if (possibly contrary to fact) the
participant were to receive control at the time of randomization (and followed until they experienced
the event). It is assumed throughout that the stable unit treatment value assumption (SUTVA)
68
(Rubin, 1980; Tipton, 2013) holds, i.e., there are no variations of treatment and there is no interference
between participants. Let S1(t) = P (T 1 > t) and S0(t) = P (T 0 > t) denote the survival functions
for the potential outcomes. Define F 1(t) = P (T 1 ≤ t) and F 0(t) = P (T 0 ≤ t) as the cumulative
distribution functions for the potential outcomes. Consistency also holds, soS(t) = S1(t)X+S0(t)(1−
X). The following additional conditions are also assumed: ignorable treatment assignment mechanism
(no unmeasured confounders) gained through randomization P (X = x|S = s,Z, T 0, T 1) = P (X =
x|S = s), ignorable trial participation mechanism conditional on Z, so P (S = s|Z, T 0, T 1) = P (S =
s|Z), and trial participation and treatment positivity P (X = x|Z, S = 1) > 0 and P (S = s|Z) > 0 for
all Z = z. Measurement of all treatment effect modifiers associated with trial participation (for both
those in the trial and cohort) will be sufficient to assume an ignorable trial participation mechanism.
Under these assumptions, one can successfully map from the observed data to the counterfactual data
needed to make inference and estimators can be expected to be consistent.
5.3 Estimators of the Marginal Survival Functions in the Target Population
The parameter of interest is the marginal survival function in the near infinite target population
at a particular time tj for each treatment group: S
1(tj) = P (T
1 > tj) and S
0(tj) = P (T
0 > tj). A
traditional (i.e., unweighted) approach to estimating treatment effects is a difference in KM estimators.
Suppose the events in the trial occur at D distinct times t1 < t2 < . . . < tD for j = 1, . . . , D
and ties are allowed. Let k index treatment with k = 1 for those randomized to treatment and
k = 0 for those randomized to control. At time tj , there are Nj0 events out of Yj0 individuals




Si(1 − Xi)δi and Yˆj0 =
∑
















if Yˆjk > 0 and t1 ≤ t. Otherwise, SˆkKM (t) = 1 if t < t1.
Two estimators that employ sampling scores are considered. The sampling scores are time-fixed
and Z is defined using participant characteristics at the baseline visit of the trial and those same
characteristics among participants in the cohort. As in Buchanan et al. (In preparation), a (weighted)
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logistic regression is used to estimate the sampling scores P (S = 1|Z = z). To account for the
random sampling of the cohort from the near infinite target, each participant in the cohort is inverse
weighted by the sampling fraction ri = m/(N − n), where N is the size of the near infinite target
population with N >> n and N >> m. Each trial participant is given a weight of ri = 1. Let
w(Z,β) = w = P (S = 1|Z), wi = w(Zi,β), and wˆi = w(Zi, βˆ). Let β0 be the vector of true values of
β1×p and βˆ1×p be the vector of estimators of β1×p. The vector of parameters β1×p can be consistently












(Manski and Lerman, 1977; Scott and Wild, 1986, 2002).

































if Yˆ wjk > 0 and t1 ≤ t. Otherwise, Sˆk(t) = 1 if t < t1.
An alternative approach for estimating survival function in the target population uses stratification
based on the estimated sampling scores (Tipton, 2013; O’Muircheartaigh and Hedges, 2013; Tipton
et al., 2014). This proposed estimator is an extension of the estimator for continuous outcomes
(Tipton, 2013) and is computed in the following steps. First, β0 is estimated using a (weighted)
logistic regression model and the sampling scores wˆi are computed. Sampling scores are used to form
L strata according to the quintiles of the distribution in the target population. Since we assume the
trial and cohort both arise from the same near infinite target, the distribution of sampling scores in
the combined trial and cohort are used to estimate the quintiles (Tipton, 2013). The survival curve
within each stratum is computed among those in the trial. Lastly, the survival curve in the target
population is estimated as a weighted sum of the survival curve across strata, where the weight wˆpl
is the proportion of observations in stratum l in the target population. Let i = 1, . . . , (n + m) index
participants and l = 1, . . . , L index stratum. For treatment group k, the stratified estimator of the









where the L stratum are defined by the distribution of the sampling scores in the near infinite target
population, k indexes treatment group and wˆpl = Nl/N with Nl as number in stratum l in the target
and N is the size of the near infinite target.
In the illustrative examples, the average standard error of all three estimators was computed using
a nonparametric bootstrap with 200 random samples with replacement of the trial and 200 random
samples with replacement of the cohort data (Efron and Tibshriani, 1994). The risk difference (RD)
at time t = tj was defined as the difference between the complement of the marginal survival curve for
k = 1 (i.e., treated group) and the complement of the marginal survival curve for k = 0 (i.e., control
group) at time t = tj . The risk ratio (RR) at time t = tj was defined as the ratio of the complement
of the marginal survival curve for k = 1 (i.e., treated group) over the complement of the marginal
survival curve for k = 0 (i.e., control group) at time t = tj .
5.4 Simulations
Simulations were performed to compare the IPSW estimator to the stratified and traditional
(i.e., unweighted) KM estimators. A total of 5,000 datasets per scenario were simulated as follows.
There were N = 106 observations in the near infinite target population and each had (Zi, wi), where
wi = {1 + exp(−β0− β1Zi)}−1 was the true sampling score. One binary covariate Zi ∼ Bern(0.2) and
one continuous covariate Zi ∼ N(0, 1), which were associated with trial participation and treatment
effect modifiers, were considered in separate scenarios. A Bernoulli trial participation indicator, Si,
was simulated according to the true sampling score wi in the target population and those with Si = 1
were included the trial. The parameters β0 and β1 were set to ensure that the probability of trial
participation was a rare event (i.e., the size of the trial was approximately n ≈ 1, 000). The cohort
was a random sample of size m = 4, 000 from the target population (less those selected into the trial)
and Si was set to zero for those included in cohort. The trial was small compared to the size of the
target, so the cohort was essentially a random sample from the target.
To estimate the weights, the combined trial (Si = 1) and cohort data (Si = 0) was used to fit
a (weighted) logistic regression model with Si as the outcome and the covariate Zi. To account for
the sampling of the cohort from the target, each participant in the cohort was inverse weighted by
rˆi = m/(N−n) in the logistic model for the sampling scores. Each trial participant was given a weight
of rˆi = 1 (in the logistic model). This allowed for unbiased estimation of the parameters in the logistic
regression model.
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For those included in the randomized trial (Si = 1), Xi was generated as Bern(0.5) and the
lognormal survival time T was generated according to T ∗i = exp(ν0 + ν1Zi + ξXi + αZiXi + i), i ∼
N(0, 1). Note the survival times are lognormal and do not follow the proportional hazards assumption.
Survival times greater than 10 years were administratively censored at that time. For scenarios 1, 2,
5, and 6, all participants were observed until the end of the study (i.e., if Ti ≤ 10, then Ti = T ∗i ).
For the remaining scenarios, there was an independent censoring mechanism Ci ∼ exp(0.5) and Ti =
min(T ∗i , Ci). For scenarios 1 to 8, ν = (ν0, ν1, ξ, α) = (0, 1, log(2), log(4)) and ν = (0, 1, log(2), log(6))
for scenarios 9 and 10. Various sampling score models were considered (i.e., weak or moderate Z and S
association): Scenarios 1, 3, 5, 7, and 9 set β = (−7, 0.4); Scenario 2, 4, 6, 8, and 10 set β = (−7, 0.6).
The true survival distributions (T 1, T 0) for each scenario were calculated using the distribution of Z
and  in the target population. When Z was binary, S(t|X = 1) = P (T > t|X = 1, Z = 1)P (Z = 1) +
P (T > t|X = 1, Z = 0)P (Z = 0) and S(t|X = 0) = P (T > t|X = 0, Z = 1)P (Z = 1) + P (T > t|X =
0, Z = 0)P (Z = 0). When Z was continuous, S(t|X = 1) = ∫
Z
P (T > t|X = 1, Z ≤ z)P (Z ≤ z)dz
and S(t|X = 0) = ∫
Z
P (T > t|X = 0, Z ≤ z)P (Z ≤ z)dz
Using all 5,000 simulated datasets, the following quantities were computed for each estimator at
time tj = 3 years: the bias, which was the difference between the average estimated survival and the
true survival, the average standard error, which was the average of the estimated bootstrap standard
errors, the empirical standard error, which was the standard deviation of the estimated survival, and
empirical coverage probability, which was the proportion of times the 95% confidence interval contained
the true survival (Table 5.2 and 5.1). The average trial size ranged from 987 to 1,091. The average
standard error of all three estimators was computed using a nonparametric bootstrap with 200 random
samples with replacement of the trial and 200 random samples with replacement of the cohort data
(Efron and Tibshriani, 1994). To obtain confidence intervals for the survival function in the proper
range, confidence intervals were computed using the log-log approach. For scenarios 4 and 10, the
estimated survival curves for each estimator were plotted for the first 100 datasets (Figure 5.1(a) to
Figure 5.2(b)). For all scenarios, the Kaplan-Meier estimator was biased for both marginal curves.
The IPSW estimator was unbiased for both marginal curves in the near infinite target population.
The stratified estimator was unbiased for both marginal curves when there was a binary covariate
in the sampling score model; however, for some scenarios with a continuous covariate, the stratified
estimator was biased and its corresponding confidence intervals had coverage below the nominal level.
The average of the bootstrap standard error was approximately equal to the Monte Carlo standard
error, supporting the utilization of the bootstrap for estimating the variance of the IPSW estimator
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and the stratified estimator.
5.5 Applications
Motivated by Gandhi et al. (2005), the IPSW estimator was employed to generalize results from
the ACTG to all people currently living with HIV in the U.S. Although the trials had internal validity,
these trial results may not be generalizable to the population of people living with HIV in the U.S.
Information on the target population was ascertained from representative cohort studies. Two target
populations were considered: all women currently living with HIV in the U.S. and all people currently
living with HIV in the U.S. The IPSW estimator was employed to generalize the ACTG results among
women using a cohort of women in the WIHS. In a separate analysis, the IPSW estimator was utilized
to generalize the trial results using a cohort defined in the Center for AIDS Research (CFAR) Network
of Integrated Clinical Systems (CNICS).
5.5.1 ACTG 320
The IPSW estimator was employed to generalize results from ACTG 320 to all people currently
living with HIV in the U.S. The ACTG 320 trial examined the safety and efficacy of adding a protease
inhibitor (PI) to an HIV treatment regimen with two nucleoside analogues. A total of 1,156 participants
were enrolled in ACTG 320 between January 1996 and January 1997 and were recruited from 33
AIDS clinical trial units and 7 National Hemophilia Foundation sites in the U.S. and Puerto Rico
(Hammer et al., 1997). 200 women were enrolled in ACTG 320 (Hammer et al., 1997). The baseline
characteristics of these women and all participants are shown in Table 5.3 and in Table 5.5, respectively.
WIHS and CNICS were considered to be representative samples of their respective target popula-
tions and this analysis only included participants who were HIV-positive, highly active antiretroviral
therapy (HAART) naive, and had CD4 cell counts ≤ 200 cells/mm3 at the previous visit (m = 493
and m = 6,158, respectively). Lab values (i.e., CD4 cell count) were carried forward for up to two
years. The WIHS is a prospective, observational, multicenter study of women living with HIV and
women at risk for HIV infection in the U.S. (Bacon et al., 2005). A total of 4,129 women (1,065
HIV-uninfected) were enrolled between October 1994 and December 2012 at six U.S. sites. Of the 493
women included in the WIHS sample, 82% were non-white, median age was 40 years, and 37% had
a history of injection drug use (IDU). The median CD4 count was 108 cells/mm3. Table 5.3 displays
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the characteristics of the women in the WIHS sample.
The CNICS captures comprehensive and standardized clinical data from point-of-care electronic
medical record systems for population-based HIV research (Kitahata et al., 2008). CNICS is considered
to be representative of all people living with HIV and in clinical care in the U.S. The CNICS cohort
includes over 27,000 HIV-infected adults (at least 18 years of age) engaged in clinical care since January
1, 1995 at eight CFAR sites in the U.S. Of the 6,158 participants included in the CNICS sample, 80%
were male, 60% were non-white, median age was 41 years, and 20% had a history of IDU. The median
CD4 count was 89 cells/mm3. Table 5.5 displays the characteristics of participants in the CNICS
sample.
The IPSW Estimator using the WIHS Cohort
The IPSW estimator was employed to assess the generalizability of the marginal survival at one
year observed among women in the ACTG 320 to all women currently living with HIV in the U.S.
Based on Centers for Disease Control (CDC) estimates, the size of the target population was assumed
to be 280,000 women (CDC, 2012). Among the 200 women in ACTG 320, 15 (8%) experienced AIDS
or death by one year with 7 of those randomized to a regimen with PI and 8 of those randomized to
a regimen without a PI. At one year, those randomized to the regimen with a PI had an estimated
AIDS-free survival of 0.93 (95% CI = (0.85, 0.97)), compared to an estimated AIDS-free survival of
0.90 (95% confidence interval (CI) = (0.79, 0.95)) for those randomized to a regimen without a PI.
Among women, there was not a statistically significant difference in the risk of AIDS or death at one
year between the two treatment groups (RD= −0.03; 95% CI = (-0.11, 0.05) and RR = 0.70; 95% CI
= (0.23, 2.09)).
The distributions of baseline age, history of IDU, and CD4 differed between the trial and cohort
participants (Table 5.3). Age, race, history of IDU, and CD4 were associated with trial participation
(P value < 0.001, P value = 0.003, P value < 0.001, and P value = 0.003, respectively). Among the
200 women in the trial, CD4 was associated with the time-to-event outcome (P value = 0.005), but
no covariates were effect modifiers on the difference scale. The estimates of the risk difference varied
across levels of all covariates, except history of IDU (Table 5.4).
To estimate the sampling scores, the data from the ACTG trial and WIHS were analyzed together,
with S = 1 for those in the ACTG trial and S = 0 for those in the WIHS cohort. A logistic regres-
sion model was fit on the combined trial and weighted cohort data. Cohort participants were inverse
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weighted by the size of the cohort divided by the size of the target (i.e., rˆi = 493/(280,000−200))
and trial participants were given a weight of rˆi = 1. The outcome was trial participation and the
possible covariates were race, age, history of IDU, and baseline CD4. Age and baseline CD4 were
modeled as continuous linear variables. Only variables associated with trial participation, the out-
come, or treatment effect modifiers were included in the sampling score model, as well as all pairwise
interactions. Using the IPSW estimator in equation (5.3), the estimated AIDS-free survival at one
year was 0.97 (95% CI = (0.86, 0.99)) among those randomized to a regimen with a PI and 0.95 (95%
CI = (0.88, 0.98)) among those randomized to the regimen without a PI. Among women, there was
not a statistically significant difference in the risk of AIDS or death at one year between the treatment
groups (RD = −0.02; 95% CI = (-0.08, 0.04) and RR = 0.58; 95% CI = (0.09, 3.84)). Figure 5.3
displays the complement of marginal survival curves estimated using the intention-to-treat (ITT) and
IPSW estimators, respectively.
The IPSW Estimator using the CNICS Cohort
The IPSW estimator was employed to assess the generalizability of the marginal survival at one
year observed in the ACTG 320 to all people currently living in the U.S. with HIV. Based on CDC
estimates, the size of the target population was assumed to be 1.1 million people (CDC, 2012). Among
the 1,156 participants in ACTG 320, 96 (8%) died or developed AIDS by one year with 33 of those
randomized to a regimen with a PI and 63 of those randomized to a regimen without a PI. At one
year, those randomized to the regimen with a PI had an estimated AIDS-free survival of 0.94 (95% CI
= (0.91, 0.95)), compared to an estimated AIDS-free survival of 0.88 (95% CI = (0.84, 0.90)) for those
randomized to a regimen without a PI. There was a statistically significant difference in the risk of
AIDS or death at one year between the treatment groups (RD = −0.06; 95% CI = (-0.10, -0.02) and
RR = 0.51; 95% CI = (0.34, 0.77)).
The distributions of baseline CD4 and IDU history differed between the trial and cohort partici-
pants (Table 5.5). Age, race, and CD4 were associated with trial participation (P value < 0.001 for
each). Among the trial participants, baseline CD4 was associated with the time-to-event outcome (P
value < 0.001) and there was effect modification on the difference scale by age (Comparing those ages
16 to <30 years to those ages 30 to <40 years (P value = 0.03)). Estimates of the risk difference varied
across levels of all covariates, except history of IDU (Table 5.6).
To estimate the sampling scores, the data from the ACTG trial and CNICS were analyzed together,
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with S = 1 for those in the ACTG trial and S = 0 for those in the CNICS cohort. A logistic regres-
sion model was fit on the combined trial and weighted cohort data. Cohort participants were inverse
weighted by the size of the cohort divided by the size of the target (i.e., rˆi = 6,158/(1,100,000−1, 156))
and trial participants were given a weight of rˆi = 1. The outcome was trial participation and the pos-
sible covariates were sex, race, age, history of IDU, and baseline CD4. Age and baseline CD4 were
modeled as continuous linear variables. Only covariates related to trial participation, the outcome,
or treatment effect modifiers were included in the sampling score model, as well as all pairwise inter-
actions. Using the IPSW estimator in equation (5.3), the estimated AIDS-free survival at one year
was 0.95 (95% CI = (0.92, 0.97)) among those randomized to a regimen with a PI and 0.89 (95% CI
= (0.87, 0.92)) among those randomized to the regimen without a PI. There was a statistically signif-
icant difference in the risk of AIDS or death at one year between the treatment groups (RD = −0.05;
95% CI = (-0.09, -0.01) and RR = 0.52; 95% CI = (0.31, 0.86)). Figure 5.4 displays the complement
of marginal survival curves estimated using the ITT and IPSW estimators, respectively.
5.5.2 ACTG A5202
The IPSW estimator was employed to generalize results from ACTG A5202 to all people currently
living with HIV in the U.S. The ACTG A5202 trial examined equivalence of abacavir-lamivudine
(ABC-3TC) or tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) plus efavirenz or ritonavir-
boosted atazanavir. A total of 1,857 participants were enrolled in ACTG A5202 between September
2005 and November 2007 and were recruited from 59 ACTG sites in the U.S. and Puerto Rico (Sax
et al., 2009, 2011). 322 women were enrolled in ACTG A5202 (Sax et al., 2009, 2011). The baseline
characteristics are shown in Table 5.7 among women and Table 5.9 among all participants.
WIHS and CNICS were considered to be representative samples of their respective target popula-
tions and this analysis only included participants who were HIV-positive, antiretroviral (ART) naive,
and had viral load > 1,000 copies/ml at the previous visit (m = 1,012 and m = 12, 302, respectively).
Of the 1, 012 women included in the WIHS sample, 83% were non-white, median age was 39 years,
38% had a history of IDU, 35% had hepatitis B or C, and 37% were diagnosed with AIDS. The median
CD4 count was 290 cells/mm3 and the median log10 viral load was 4.61 copies/ml. Table 5.7 displays
the characteristics of the women in the WIHS sample. Of the 12,302 participants included in the
CNICS sample, 82% were male, 55% were non-white, median age was 39 years, 17% had a history of
IDU, 18% had hepatitis B or C, and 23% were diagnosed with AIDS. The median CD4 count was 271
cells/mm3 and the median log10 viral load was 4.64 copies/ml. Table 5.9 displays the characteristics
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of participants in the CNICS sample.
The IPSW Estimator using the WIHS Cohort
The IPSW estimator was employed to assess the generalizability of the probability of virologic
failure at week 48 for each treatment group (ABC-3TC vs. TDF-FTC) observed among women in
the ACTG A5202 to all women currently living with HIV in the U.S. Based on CDC estimates, the
size of the target population was assumed to be 280,000 women (CDC, 2012). The outcome analyzed
was time to virologic failure (defined as confirmed HIV-1 RNA level ≥ 1000 copies per milliliter at or
after 16 weeks and before 24 weeks, or ≥ 200 copies per milliliter at or after 24 weeks). Among the
322 women in A5202, 49 (15%) experienced virologic failure by week 48 with 26 of those randomized
to ABC-3TC and 23 of those randomized to TDF-FTC. The estimated probability of remaining free
of virologic failure beyond week 48 was 0.86 (95% CI = (0.80, 0.91)) among those on ABC-3TC,
compared to 0.91 (95% CI = (0.84, 0.94)) among those on TDF-FTC. Among women, there was not
a statistically significant difference between the treatment groups (RD = 0.04; 95% CI = (-0.03, 0.11)
and RR = 1.43; 95% CI = (0.73, 2.78)).
The distributions of baseline CD4, history of IDU, hepatitis, and AIDS differed between the trial
and cohort participants (Table 5.7). Age, history of IDU, hepatitis, AIDS diagnosis, baseline CD4,
and viral load were associated with trial participation (P value = 0.004, P value < 0.001, P value
= 0.003, P value < 0.001, P value < 0.001, and P value < 0.001, respectively). Among the trial
participants, age, AIDS diagnosis, and baseline CD4 were associated with the time-to-event outcome
(P value = 0.04, P value = 0.04, and P value = 0.03, respectively). There was no effect modification
on the difference scale by any of the covariates. The estimates of the risk difference varied across levels
of all covariates, except history of IDU (Table 5.8).
To estimate the sampling scores, the data from the ACTG trial and WIHS were analyzed together,
with S = 1 for those in the ACTG trial and S = 0 for those in the WIHS cohort. A logistic regression
model was fit on the combined trial and weighted cohort data. Cohort participants were inverse
weighted by the size of the cohort divided by the size of the target (i.e., rˆi = 1, 012/(280,000−322))
and trial participants were given a weight of rˆi = 1. The outcome was trial participation and the
possible covariates were race, age, history of IDU, hepatitis B/C, AIDS diagnosis, and baseline CD4,
and baseline log10 viral load. Only variables associated with either trial participation, the outcome or
effect modifiers were included in the sampling score model, as well as all pairwise interactions. Age,
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baseline CD4, and baseline log10 viral load were modeled as continuous linear variables. Because
hepatitis B/C and history of IDU were correlated (r = 0.69), history of IDU was excluded from the
sampling score model.
Using the IPSW estimator in equation (5.3), the marginal survival estimates of virologic failure
at week 48 for each treatment group were computed. The estimated probability of remaining free
of virologic failure beyond week 48 was 0.82 (95% CI = (0.58, 0.93)) among those on ABC-3TC,
compared to 0.90 (95% CI = (0.79, 0.96)) among those on TDF-FTC. Among women, there was not
a statistically significant difference between the treatment groups (RD = 0.08; 95% CI = (-0.12, 0.28)
and RR = 1.80; 95% CI = (0.54, 6.05)). Figure 5.5 displays the complement of marginal survival
curves estimated using the ITT and IPSW estimators, respectively.
The IPSW Estimator using the CNICS Cohort
The IPSW estimator was employed to assess the generalizability of the marginal probability of
virologic failure at week 48 between the ABC-3TC and TDF-FTC treatment groups observed in the
ACTG A5202 to all people currently living with HIV in the U.S. Based on CDC estimates, the size of
the target population was assumed to be 1.1 million people (CDC, 2012). Among the 1,857 participants
in A5202, 219 (12%) experienced virologic failure by week 48 with 131 of those randomized to ABC-
3TC and 88 of those randomized to TDF-FTC. The estimated probability of remaining free of virologic
failure beyond week 48 was 0.88 (95% CI = (0.85, 0.90)) among those on ABC-3TC, compared to 0.93
(95% CI = (0.92, 0.95)) among those on TDF-FTC. Among all participants, there was a statistically
significant difference between the treatment groups (RD = 0.05; 95% CI = (0.03, 0.08) and RR =
1.83; 95% CI = (1.33, 2.52)).
The distributions of history of IDU, hepatitis, AIDS diagnosis, and baseline CD4 differed between
the trial and cohort participants (Table 5.9). Race, AIDS diagnosis, hepatitis B/C, history of IDU,
CD4, and viral load were associated with trial participation (P value < 0.001 for each). Among
the trial participants, age, race, hepatitis B/C, AIDS diagnosis, baseline CD4, and viral load were
associated with the outcome (P value < 0.001, P value < 0.001, P value = 0.002, P value < 0.001,
P value < 0.001, and P value = 0.001, respectively). There was effect modification on the difference
scale by CD4 (100 to 200 cells/mm3 versus < 50 cells/mm3 (P value = 0.05)) and viral load (100,000
to 300,000 copies/ml versus < 50,000 copies/ml (P value = 0.05) and > 500, 000 copies/ml versus
< 50, 000 copies/ml (P value = 0.04)). The estimates of the risk difference varied across levels of all
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covariates (Table 5.10).
To estimate the sampling scores, the data from the ACTG trial and CNICS were analyzed together,
with S = 1 for those in the ACTG trial and S = 0 for those in the CNICS cohort. A logistic regression
model was fit on the combined trial and weighted cohort data. Cohort participants were inverse
weighted by the size of the cohort divided by the size of the target (i.e., rˆi = 12, 302/(280,000−1, 857))
and trial participants were given a weight of rˆi = 1. The outcome was trial participation and possible
covariates were sex, race, age, history of IDU, hepatitis B/C, AIDS diagnosis, baseline CD4 and
baseline log10 viral load. Age, baseline CD4, and baseline log10 viral load were modeled as continuous
linear variables. Only covariates associated with trial participation, the outcome, or effect modifiers
were included in the sampling score model, as well as all pairwise interactions.
Using the IPSW estimator in equation (5.3), the marginal survival estimates of virologic failure
at week 48 for each regimen group were computed. The estimated probability of remaining free
of virologic failure beyond week 48 was 0.87 (95% CI = (0.84, 0.90)) among those on ABC-3TC,
compared to 0.93 (95% CI = (0.91, 0.95)) among those on TDF-FTC. Among all participants, there
was a statistically significant difference between the treatment groups (RD = 0.06; 95% CI = (0.02,
0.10) and RR = 1.83; 95% CI = (1.23, 2.72)). Figure 5.6 displays the complement of marginal survival
curves estimated using the ITT and IPSW estimators, respectively.
5.6 Discussion
Following Cole and Stuart (2010) and Buchanan et al. (In preparation), we considered an esti-
mator using inverse probability of sampling weights to generalize results for right-censored data in a
randomized trial to a specified target population. We use the term generalizability to describe the
degree to which an internally valid measure of effect estimated in a sample from one population would
change if the trial were conducted in a different target population. The IPSW estimator compares
the outcome in the target population if (possibly contrary to fact) everyone had been randomized to
treatment with the outcome in the target population if (possibly contrary to fact) everyone had been
randomized to control. Simulation results were provided to compare this estimator to an unweighted
KM estimator and a stratified estimator. The average standard error was computed using a non-
parametric bootstrap. In the following, we discuss some recent work addressing generalizability and
explore caveats of this approach.
In the illustrative example, the IPSW estimator was employed to generalize results for right-
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censored data in the ACTG to all people currently living with HIV in the U.S. For both trials, the risk
difference estimated with the ITT was comparable to the risk difference estimated with the IPSW.
Thus, the ACTG 320 results appear to be generalizable to all people living with HIV in the U.S.
Among women in A5202, the risk difference doubled when calculated with the IPSW estimator, as
compared to the ITT estimator (RD = 0.08 vs. RD = 0.04, respectively). The marginal event rates
typically had a larger change in magnitude than the relative measures (i.e., risk difference and risk
ratio). Results were not sensitive to the specification of the size of the target population.
In a previous paper by Cole and Stuart (2010), the ACTG 320 results were generalized to a
target population of all people infected with HIV in the U.S. in 2006, as estimated by the CDC.
This paper continues that effort by empirically demonstrating the reasonable performance of the
bootstrap standard error, as well using cohort data to obtain richer information on the target. This
paper continues the effort in Tipton (2013) by extending their estimator for right-censored data and
evaluating the performance of the nonparametric bootstrap standard error for this estimator.
When applying this method, the analysis is subject to the following considerations. The nonpara-
metric bootstrap standard error was used to estimate the variance. Additional research to demonstrate
the large sample properties of this estimator could allow for a closed-form expression for the variance.
The absence of unmeasured covariates associated with the trial participation and treatment effect
modifiers is an untestable assumption. Treatment compliance issues were ignored in this method;
however, this issue could be considered in analyses. The sampling score model was assumed to be cor-
rect; however, this is not guaranteed in practice. Weighted logistic regression was used as an approach
to consistently estimate the parameters of the logistic regression model (i.e., the intercept); however,
other approaches may be possible. Future research could extend the IPSW estimator to a doubly-
robust estimator (Bang and Robins, 2005). This method could also be extended to accommodate the
presence of interference.
In conclusion, we considered an inverse probability of sampling weighted estimator for estimating
marginal survival curves in the target population. The bootstrap standard error appears to be a
reasonable estimator of the variance for the IPSW estimator. Quantitative methods for generalizability
is a growing field of statistical research and methods for right-censored data are essential to address
questions in infectious disease research. We hope that this paper will be useful for implementation of
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Table 5.1: Summary of Monte Carlo results for estimators of the marginal survival curves
in the target population with a right-censored outcome for X = 1 with m = 4,000 and
n ≈ 1,000 in 5,000 simulated datasets. Scenarios are described in the text. Bias, average
standard error (ASE) (× 100), empirical standard error (ESE) (× 100), and 95% empirical
coverage probability (ECP) at tj = 3 are reported for each estimator. Sˆ
1
IPSW (tj) is the
inverse probability of sampling weighted estimator, Sˆ1S(tj) is the stratified estimator, and
Sˆ1KM (tj) is the Kaplan-Meier estimator. For scenarios 1 to 4, S
1(tj) = 0.47, for scenarios
5 to 8, S1(tj) = 0.44, and, for scenarios 9 and 10, S
1(tj) = 0.45.





Bias ASE ESE ECP Bias ASE ESE ECP Bias ASE ESE ECP
1 Bin (0.4,4) Adm 9e-5 2.2 2.2 0.95 6e-5 2.1 2.1 0.95 0.05 2.2 2.3 0.49
2 Bin (0.6,4) Adm -2e-4 2.2 2.2 0.94 -3e-4 2.0 2.1 0.94 0.07 2.2 2.2 0.10
3 Bin (0.4,4) Ind -1e-3 3.6 3.6 0.95 -1e-3 3.3 3.3 0.95 0.04 3.5 3.5 0.77
4 Bin (0.6,4) Ind 1e-3 3.5 3.6 0.95 6e-4 3.3 3.4 0.95 0.07 3.4 3.4 0.47
5 Con (0.4,4) Adm 4e-4 2.1 2.2 0.95 5e-3 1.6 1.6 0.93 0.15 2.2 2.2 <0.01
6 Con (0.6,4) Adm 5e-4 2.3 2.3 0.95 8e-3 1.6 1.6 0.93 0.22 2.0 2.0 <0.01
7 Con (0.4,4) Ind 8e-4 3.1 3.1 0.95 6e-3 2.5 2.4 0.94 0.15 3.1 3.1 <0.01
8 Con (0.6,4) Ind 2e-3 3.2 3.2 0.95 0.01 2.5 2.5 0.93 0.22 2.9 2.9 <0.01
9 Con (0.4,6) Ind 1e-3 3.0 3.0 0.95 7e-3 2.3 2.3 0.95 0.15 3.0 3.0 <0.01
10 Con (0.6,6) Ind 2e-3 3.2 3.2 0.95 0.01 2.4 2.3 0.93 0.22 2.8 2.9 <0.01
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Table 5.2: Summary of Monte Carlo results for estimators of the marginal survival curves
in the target population with a right-censored outcome for X = 0 with m = 4,000 and
n ≈ 1,000 in 5,000 simulated datasets. Scenarios are described in the text. Bias, average
standard error (ASE) (× 100), empirical standard error (ESE) (× 100), and 95% empirical
coverage probability (ECP) at tj = 3 are reported for each estimator. Sˆ
0
IPSW (tj) is the
inverse probability of sampling weighted estimator, Sˆ0S(tj) is the stratified estimator, and
Sˆ0KM (tj) is the Kaplan-Meier estimator. For scenarios 1 to 4, S
0(tj) = 0.20 and, for
scenarios 5 to 10, S0(tj) = 0.22.





Bias ASE ESE ECP Bias ASE ESE ECP Bias ASE ESE ECP
1 Bin (0.4,4) Adm -2e-4 1.7 1.7 0.95 -2e-4 1.7 1.7 0.95 0.02 1.9 1.9 0.76
2 Bin (0.6,4) Adm 3e-4 1.7 1.7 0.95 2e-4 1.7 1.7 0.95 0.04 1.9 1.8 0.47
3 Bin (0.4,4) Ind 3e-4 2.9 2.9 0.95 6e-5 2.8 2.8 0.96 0.02 3.0 3.0 0.87
4 Bin (0.6,4) Ind 6e-4 2.8 2.8 0.95 6e-4 2.7 2.7 0.95 0.04 3.0 3.0 0.76
5 Con (0.4,4) Adm 2e-4 1.7 1.7 0.95 9e-3 1.5 1.5 0.92 0.09 2.1 2.1 <0.01
6 Con (0.6,4) Adm 4e-4 1.7 1.7 0.95 0.01 1.5 1.5 0.86 0.14 2.1 2.1 <0.01
7 Con (0.4,4) Ind 6e-4 2.7 2.7 0.95 0.01 2.6 2.6 0.93 0.09 3.3 3.3 0.17
8 Con (0.6,4) Ind 2e-4 2.6 2.6 0.95 0.02 2.5 2.5 0.91 0.14 3.2 3.2 <0.01
9 Con (0.4,6) Ind 6e-4 2.7 2.7 0.95 0.01 2.6 2.6 0.93 0.09 3.3 3.3 0.17
10 Con (0.6,6) Ind 2e-4 2.6 2.6 0.95 0.02 2.5 2.5 0.91 0.14 3.2 3.2 <0.01
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Table 5.3: Characteristics of 493 women in the Women’s Interagency HIV Study (WIHS)
who were HIV-positive, HAART naive, and had CD4 cell count ≤ 200 cells/mm3 at the
previous visit and 200 women at baseline in AIDS Clinical Trials Group (ACTG) 320 by
treatment group (with and without a protease inhibitor (PI))
WIHS ACTG 320 ACTG 320 ACTG 320
Protease No Protease
Inhibitor (PI) Inhibitor (PI)
Variable (m = 493) (n = 200) (n1 = 106) (n0 = 94)
Race or ethnic group - no. (%)
White, non-Hispanic 87 (18) 61 (31) 26 (25) 35 (37)
Black, non-Hispanic 272 (55) 95 (48) 54 (51) 41 (44)
Hispanic 124 (25) 42 (21) 25 (24) 17 (18)
Asian/Other 10 (2) 2 (1) 1 (1) 1 (1)
Median age - yr (Q1-Q3) 40 (35-45) 36 (30-42) 37 (31-42) 36 (30-43)
Age group - no. (%)
16-<30 yr 35 (7) 46 (23) 22 (21) 24 (26)
30-<40 yr 211 (43) 88 (44) 48 (45) 40 (43)
40-<50 yr 196 (40) 53 (27) 27 (26) 26 (28)
≥50 yr 51 (10) 13 (7) 9 (9) 4 (4)
Injection drug use - no. (%) 180 (37) 36 (18) 24 (23) 12 (13)
Median CD4 count (Q1-Q3) 108 (41-172) 82 (26-139) 93 (29-139) 70 (23-138)
Baseline CD4 count - no. (%)
<50 cells/mm3 148 (30) 72 (36) 35 (33) 37 (39)
50-<100 cells/mm3 83 (17) 43 (22) 22 (21) 21 (22)
100-<200 cells/mm3 182 (37) 73 (37) 44 (42) 29 (31)
≥200 cells/mm3 80 (16) 12 (6) 5 (5) 7 (7)
84
Table 5.4: Difference in the estimated risk of AIDS or death at one year between treatment
groups (protease inhibitor (PI) vs. no PI) for each level of the covariates among 200 women
in AIDS Clinical Trials Group 320 with corresponding 95% confidence interval (CI)
Variable AIDS or Death
at One Year
Risk Difference (95 % CI)
Race or ethnic group
White, non-Hispanic 0.01 (-0.25, 0.27)




18-<30 yr 0.15 (-0.10, 0.39)
30-<40 yr -0.09 (-0.26, 0.07)




No -0.04 (-0.17, 0.10)
Baseline CD4 count
<50 cells/mm3 0 (-0.26, 0.24)
50-<100 cells/mm3 -0.05 (-0.26, 0.16)
100-<200 cells/mm3 -0.02 (-0.16, 0.12)
≥200 cells/mm3 -a
aNo events in this stratum.
bNo events in this stratum among those randomized to a PI.
cNo events in this stratum among those randomized to no PI.
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Table 5.5: Characteristics of 6,158 participants in the CFAR Network of Integrated Clinical
Systems (CNICS) who were HIV-positive, HAART naive, and had CD4 cell count ≤ 200
cells/mm3 at the previous visit and 1,156 participants at baseline in AIDS Clinical Trials
Group (ACTG) 320 by treatment group (with and without a protease inhibitor (PI))
CNICS ACTG 320 ACTG 320 ACTG 320
Protease No Protease
Inhibitor (PI) Inhibitor (PI)
Variable (m = 6,158) (n = 1,156) (n1 = 577) (n0 = 579)
Male sex - no. (%) 4,909 (80) 956 (83) 471 (82) 485 (84)
Race or ethnic group - no. (%)
White, non-Hispanic 2,436 (40) 598 (52) 303 (53) 295 (51)
Black, non-Hispanic 2,690 (44) 328 (28) 163 (28) 165 (29)
Hispanic 734 (12) 205 (18) 99 (17) 106 (18)
Asian/Other 298 (5) 25 (2) 12 (2) 13 (2)
Median age - yr (Q1-Q3) 41 (34-47) 38 (33-44) 38 (33-44) 38 (33-44)
Age group - no. (%)
16-<30 yr 714 (12) 142 (12) 69 (12) 73 (13)
30-<40 yr 2,108 (34) 536 (47) 272 (47) 264 (46)
40-<50 yr 2,315 (38) 350 (30) 169 (29) 181 (31)
≥50 yr 1,021 (17) 128 (11) 67 (12) 61 (11)
Injection drug use - no. (%) 1,241 (20) 184 (16) 91 (16) 93 (16)
Median CD4 count (Q1-Q3) 89 (27-172) 75 (23-137) 80 (24-138) 70 (23-135)
Baseline CD4 count - no. (%)a
<50 cells/mm3 2,237 (36) 453 (39) 219 (38) 234 (41)
50-<100 cells/mm3 1,047 (17) 248 (22) 118 (20) 130 (23)
100-<200 cells/mm3 1,818 (30) 372 (32) 200 (35) 172 (30)
≥200 cells/mm3 1,056 (17) 82 (7) 40 (7) 42 (7)
aOne A5202 participant missing baseline CD4 cell count.
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Table 5.6: Difference in the estimated risk of AIDS or death at one year between treatment
groups (protease inhibitor (PI) vs. no PI) for each level of the covariates among 1,156
participants in AIDS Clinical Trials Group (ACTG) 320 with corresponding 95% confidence
interval (CI)
Variable AIDS or Death
at One Year
Risk Difference (95 % CI)
Sex
Male -0.07 (-0.12, -0.01)
Female -0.03 (-0.15, 0.09)
Race or ethnic group
White, non-Hispanic -0.05 (-0.12, 0.02)
Black, non-Hispanic -0.08 (-0.17, 0.01)
Hispanic -0.07 (-0.21, 0.07)
Asian/Other -0.11 (-0.57, 0.35)
Age group
16-<30 yr 0.04 (-0.09, 0.16)
30-<40 yr -0.12 (-0.19, -0.05)
40-<50 yr -0.02 (-0.11, 0.08)
≥50 yr -0.05 (-0.24, 0.13)
Injection drug use
Yes -0.06 (-0.17, 0.04)
No -0.06 (-0.12, -0.002)
Baseline CD4 count
<50 cells/mm3 -0.09 (-0.19, 0.01)
50-<100 cells/mm3 -0.06 (-0.17, 0.04)
100-<200 cells/mm3 -0.03 (-0.08, 0.02)
≥200 cells/mm3 -a
aNo events in this stratum among those randomized to no PI.
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Table 5.7: Characteristics of 1,012 women in the Women’s Interagency HIV Study (WIHS)
who were HIV-positive, ART naive, and had viral load> 1000 copies/ml at the previous visit
and 322 women at baseline in AIDS Clinical Trials Group (ACTG) A5202 by treatment
group (abacavir-lamivudine (ABC-3TC) vs. tenofovir disoproxil fumarate-emtricitabine
(TDF-FTC))
WIHS ACTG A5202 ACTG A5202 ACTG A5202
ABC-3TC TDF FTC
Variable (m = 1,012) (n = 322) (n1 = 173) (n0 = 149)
Race or ethnic group - no. (%)
White, non-Hispanic 171 (17) 57 (18) 30 (17) 27 (18)
Black, non-Hispanic 586 (58) 172 (53) 94 (54) 78 (52)
Hispanic 222 (22) 82 (26) 42 (24) 40 (27)
Asian/Other 33 (3) 11 (3) 7 (4) 4 (3)
Median age - yr (Q1-Q3) 39 (33-44) 39 (31-46) 39 (31-46) 39 (31-46)
Age group - no. (%)
16-<30 yr 123 (12) 57 (18) 30 (17) 27 (18)
30-<40 yr 435 (43) 110 (34) 62 (36) 48 (32)
40-<50 yr 345 (34) 107 (33) 54 (31) 53 (36)
≥50 yr 109 (11) 48 (15) 27 (16) 21 (14)
Injection drug use - no. (%) 388 (38) 18 (6) 9 (5) 9 (6)
Hepatitis B/C - no. (%) 356 (35) 25 (8) 14 (8) 11 (7)
AIDS diagnosis - no. (%) 373 (37) 62 (19) 39 (23) 23 (15)
CD4 count - no. (%)
<50 cells/mm3 102 (10) 61 (19) 38 (22) 23 (15)
50-<100 cells/mm3 61 (6) 24 (7) 15 (8) 9 (6)
100-<200 cells/mm3 162 (16) 55 (17) 28 (16) 27 (18)
200-<350 cells/mm3 295 (29) 130 (40) 65 (38) 65 (44)
≥350 cells/mm3 392 (39) 52 (16) 4 (6) 25 (17)
Median CD4 count (Q1-Q3) 290 (162-423) 226 (87-313) 209 (60-308) 249 (129-316)
Viral load - no. (%)
<50,000 cp/ml 552 (55) 187 (58) 93 (54) 94 (63)
50,000-<100,000 cp/ml 144 (14) 62 (19) 33 (19) 29 (20)
100,000-<300,000 cp/ml 193 (19) 38 (12) 24 (14) 14 (9)
300,000-<500,000 cp/ml 55 (5) 9 (3) 6 (3) 3 (2)
≥500,000 cp/ml 68 (7) 26 (8) 17 (10) 9 (6)
Median log10 viral load (Q1-Q3) 4.61 (4.04-5.11) 4.58 (4.07-4.93) 4.62 (4.10-5.09) 4.55 (4.04-4.86)
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Table 5.8: Difference in the estimated risk of virolgic failure at week 48 between treatment
groups (abacavir-lamivudine (ABC-3TC) vs. tenofovir disoproxil fumarate-emtricitabine
(TDF-FTC)) for each level of the covariates among 322 women in AIDS Clinical Trials
Group A5202 with corresponding 95% confidence interval (CI)
Variable Virologic Failure
at Week 48
Risk Difference (95 % CI)
Race or ethnic group
White, non-Hispanic -a
Black, non-Hispanic 0.03 (-0.13, 0.19)
Hispanic -0.06 (-0.19, 0.08)
Asian/Other -b
Age group
18-<30 yr 0.07 (-0.13, 0.26)
30-<40 yr 0.03 (-0.16, 0.22)




No 0.04 (-0.07, 0.15)
Hepatitis B/C
Yes -0.02 (-0.45, 0.41)
No 0.04 (-0.06, 0.15)
AIDS diagnosis
Yes 0.10 (-0.16, 0.37)
No 0.02 (-0.09, 0.13)
CD4 count
<50 cells/mm3 0.11 (-0.16, 0.38)
50-<100 cells/mm3 -0.14 (-0.66, 0.39)
100-<200 cells/mm3 0.00 (-0.15, 0.16)
200-<350 cells/mm3 0.01 (-0.15, 0.16)
≥350 cells/mm3 0.11 (-0.22, 0.43)
Viral load
<50,000 cp/ml 0.06 (-0.06, 0.18)
50,000-<100,000 cp/ml -d
100,000-<300,000 cp/ml 0.16 (-0.27, 0.60)
300,000-<500,000 cp/ml 0 (-1.07, 1.07)
≥500,000 cp/ml -b
aNo events before week 48 in the TDF-FTC arm.
bNo events in the TDF-FTC arm.
cNo events in the ABC-3TC arm.
dNo events before week 48 in the ABC-3TC arm.
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Table 5.9: Characteristics of 12,302 participants in the CFAR Network of Integrated Clin-
ical Systems (CNICS) who were HIV-positive, ART naive, and had viral load > 1000
copies/ml at the previous visit and 1,857 participants at baseline in AIDS Clinical Trials
Group (ACTG) A5202 by treatment group (abacavir-lamivudine (ABC-3TC) vs. tenofovir
disoproxil fumarate-emtricitabine (TDF-FTC))
CNICS ACTG A5202 ACTG A5202 ACTG A5202
ABC-3TC TDF FTC
Variable (m = 12,302) (n =1,857) (n1 = 928) (n0 = 929)
Male sex - no. (%) 10,063 (82) 1,535 (83) 755 (81) 780 (84)
Race or ethnic groupa - no. (%)
White, non-Hispanic 5,567 (45) 746 (46) 363 (39) 383 (41)
Black, non-Hispanic 4,682 (38) 615 (33) 317 (34) 298 (32)
Hispanic 1,420 (12) 429 (23) 214 (23) 215 (23)
Asian/Other 633 (5) 62 (3) 31 (3) 31 (3)
Median age - yr (Q1-Q3) 39 (31-46) 38 (31-45) 38 (30-45) 39 (31-45)
Age group - no. (%)
16-<30 yr 2,454 (20) 404 (22) 201 (22) 203 (22)
30-<40 yr 4,225 (34) 625 (34) 335 (36) 290 (31)
40-<50 yr 3,896 (32) 573 (31) 273 (29) 300 (32)
≥50 yr 1,727 (14) 255 (14) 119 (13) 136 (15)
Injection drug use - no. (%) 2,042 (17) 162 (9) 77 (8) 85 (9)
Hepatitis B/C - no. (%) 2,245 (18) 165 (9) 75 (8) 90 (10)
AIDS diagnosis - no. (%) 2,834 (23) 312 (17) 172 (19) 140 (15)
CD4 count- no. (%)b - no. (%)
<50 cells/mm3 2,000 (16) 339 (18) 176 (19) 163 (18)
50-<100 cells/mm3 920 (7) 150 (8) 74 (8) 76 (8)
100-<200 cells/mm3 1,692 (14) 311 (17) 159 (17) 152 (16)
200-<350 cells/mm3 3,262 (27) 656 (35) 312 (34) 344 (37)
≥350 cells/mm3 4,428 (36) 400 (22) 207 (22) 193 (21)
Median CD4 count (Q1-Q3) 271 (109-427) 230 (90-334) 229 (84-338) 230 (96-330)
Viral load - no. (%)
<50,000 cp/ml 6,450 (52) 1,000 (54) 492 (53) 508 (55)
50,000-<100,000 cp/ml 1,861 (15) 391 (21) 196 (21) 195 (21)
100,000-<300,000 cp/ml 2,232 (18) 203 (11) 106 (11) 97 (10)
300,000-<500,000 cp/ml 744 (6) 72 (4) 38 (4) 34 (4)
≥500,000 cp/ml 1,015 (8) 191 (10) 96 (10) 95 (10)
Median log10 viral load (Q1-Q3) 4.64 (3.95-5.18) 4.66 (4.33-5.01) 4.66 (4.31-5.06) 4.65 (4.34-4.96)
aFive A5202 participants were missing race.
bOne A5202 participant was missing CD4.
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Table 5.10: Difference in the estimated risk of virolgic failure at week 48 between treatment
groups (abacavir-lamivudine (ABC-3TC) vs. tenofovir disoproxil fumarate-emtricitabine
(TDF-FTC)) for each level of the covariates among 1,857 participants in ACTG A5202
with corresponding 95% confidence interval (CI)
Variable Virologic Failure
at Week 48
Risk Difference (95 % CI)
Sex
Male 0.06 (0.01, 0.10)
Female 0.04 (-0.06, 0.14)
Race or ethnic group
White, non-Hispanic 0.07 (0.02, 0.13)
Black, non-Hispanic 0.04 (-0.04, 0.12)
Hispanic 0.01 (-0.06, 0.08)
Asian/Other -a
Age group
18-<30 yr 0.09 (0.004, 0.17)
30-<40 yr 0.08 (0.004, 0.15)
40-<50 yr 0.03 (0.04, 0.10)
≥50 yr -0.02 (-0.10, 0.07)
Injection drug use
Yes 0.11 (-0.03, 0.24)
No 0.05 (0.01, 0.09)
Hepatitis B/C
Yes -0.003 (-0.16, 0.16)
No 0.06 (0.02, 0.10)
AIDS diagnosis
Yes 0.12 (0.002, 0.23)
No 0.04 (-0.002, 0.08)
CD4 count
<50 cells/mm3 0.15 (0.03, 0.27)
50-<100 cells/mm3 0.11 (-0.03, 0.26)
100-<200 cells/mm3 0.01 (-0.08, 0.09)
200-<350 cells/mm3 0.03 (-0.02, 0.08)
≥350 cells/mm3 0.02 (-0.06, 0.11)
Viral load
<50,000 cp/ml 0.02 (-0.03, 0.06)
50,000-<100,000 cp/ml 0.02 (-0.06, 0.10)
100,000-<300,000 cp/ml 0.16 (0.02, 0.30)
300,000-<500,000 cp/ml 0.14 (-0.11, 0.39)
≥500,000 cp/ml 0.18 (0.03, 0.33)
aNo events in the TDF-FTC arm.
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Table 5.11: Results for the risk difference of the time-to-event outcomes with corresponding
95% confidence intervals in two AIDS Clinical Trials Group studies, where the sampling
score model included variables associated with trial participation, the outcome, or effect
modifiers (with a linear term for continuous variables) and all pairwise interactions
Cohort Trial ITT IPSW Stratified
WIHS 320a -0.03 (-0.11, 0.05) -0.02 (-0.08, 0.04) -0.01 (-0.12, 0.09)
WIHS A5202b 0.04 (-0.03, 0.11) 0.08 (-0.12, 0.28) 0.12 (-0.10, 0.26)
CNICS 320 -0.06 (-0.10, -0.02) -0.05 (-0.09, -0.01) -0.06 (-0.09, -0.02)
CNICS A5202 0.05 (0.03, 0.08) 0.06 (0.02, 0.10) 0.07 (0.02, 0.10)
aFor 320, the treatment contrast was PI vs. no PI.
bFor A5202, the treatment contrast was ABC-3TC vs. TDF-FTC.
Table 5.12: Results for the risk ratio of the time-to-event outcomes with corresponding 95%
confidence intervals in two AIDS Clinical Trials Group studies, where the sampling score
model included variables associated with trial participation, the outcome, or effect modifiers
(with a linear term for continuous variables) and all pairwise interactions
Cohort Trial ITT IPSW Stratified
WIHS 320a 0.70 (0.23, 2.09) 0.58 (0.09, 3.84) 0.85 (0.12, 2.84)
WIHS A5202b 1.43 (0.73, 2.78) 1.80 (0.54, 6.05) 2.32 (0.54, 6.00)
CNICS 320 0.51 (0.34, 0.77) 0.52 (0.31, 0.86) 0.48 (0.32, 0.85)
CNICS A5202 1.83 (1.33, 2.52) 1.83 (1.23, 2.72) 2.02 (1.16, 2.88)
aFor 320, the treatment contrast was PI vs. no PI.
bFor A5202, the treatment contrast was ABC-3TC vs. TDF-FTC.
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(a) Simulation results with a binary covariate for X = 0

























































(b) Simulation results with a binary covariate for X = 1
Figure 5.1: Comparison of the distributions of the inverse probability of sampling weighted
estimator and the Kaplan-Meier estimator based on 100 simulated datasets with a right-
censored outcome, independent censoring and one binary covariate for β = (−7, 0.6) and
eα = 4 (red line is the true survival curve in the target population)
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(a) Simulation results with a continuous covariate for X = 0

























































(b) Simulation results with a continuous covariate for X = 1
Figure 5.2: Comparison of the distributions of the inverse probability of sampling weighted
estimator and the Kaplan-Meier estimator based on 100 simulated datasets with a right-
censored outcome, independent censoring and one continuous covariate for β = (−7, 0.6) and
and eα = 6 (red line is the true survival curve in the target population)
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Figure 5.3: Complement of the Kaplan-Meier survival curves among women randomized to
a regimen with a protease inhibitor (PI) (solid curves) and without a PI (dashed curves) in
AIDS Clinical Trial Group 320 Study using intent-to-treat (left panel) and inverse probability
of sampling weighted estimators (right panel). Representative cohort based on data from the
Women’s Interagency HIV Study.














































Figure 5.4: Complement of the Kaplan-Meier survival curves among participants randomized
to a regimen with a protease inhibitor (PI) (solid curves) and without a PI (dashed curves) in
AIDS Clinical Trial Group 320 Study using intent-to-treat (left panel) and inverse probability
of sampling weighted estimators (right panel). Representative cohort based on data from the
Center for AIDS Research Network of Integrated Clinical Systems.
95


















































Figure 5.5: Complement of the Kaplan-Meier survival curves among those random-
ized to abacavir-lamivudine (ABC-3TC) (solid curves) and tenofovir disoproxil fumarate-
emtricitabine (TDF-FTC) (dashed curves) in AIDS Clinical Trial Group A5202 Study using
intent-to-treat (left panel) and inverse probability of sampling weighted estimators (right
panel). Representative cohort based on data from the Women’s Interagency HIV Study.
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Figure 5.6: Complement of the Kaplan-Meier survival curves among participants random-
ized to abacavir-lamivudine (ABC-3TC) (solid curves) and tenofovir disoproxil fumarate-
emtricitabine (TDF-FTC) (dashed curves) in AIDS Clinical Trial Group A5202 Study using
intent-to-treat (left panel) and inverse probability of sampling weighted estimators (right




To summarize, estimating causal effects may require consideration of both internal and external
validity. For estimating effects in a study sample, addressing both confounding and selection bias are
necessary. In Chapter 3, we continued the effort of improving understanding and utilization of causal
inference methods to address confounding and selection bias in observational studies. We summarized
the literature for IP-weighted Cox models through a comparison to the traditional Cox model and
provided an illustrative example in HIV/AIDS research.
Estimation of causal effects in the target population requires both internal and external validity.
We developed and applied methods for assessing generalizability of internally valid results. Following
Cole and Stuart (2010) and Stuart et al. (2011), we considered an inverse probability of sampling
weighted estimator in Chapter 4 for generalizing trial results to a target population, where the pa-
rameter of interest is a difference in average potential outcomes in a target population. In Chapter
5, we considered this estimator for right-censored data defined as an inverse weighted Kaplan-Meier
estimator and empirically evaluated the performance of the nonparametric bootstrap standard error.
There are several future directions for this research. The appropriate method for choosing the
covariates for the sampling score model remains an open question; however, methodology developed
for treatment propensity scores may be extend for sampling score models (Brookhart et al., 2006;
VanderWeele and Shpitser, 2011). In the case that there is residual treatment confounding in the trial,
additional methodology will be needed to estimate effects. We suggest using an inverse probability of
treatment weight; however, the statistical properties of this method need to be formally shown. The
sampling score model was assumed to be correct; however, this may not always happen in practice. This
method could be extended using a doubly-robust approach to address this concern (Bang and Robins,
2005). Quantitative methods for causal inference and generalizability is a growing field of statistical
research. We hope that this body of work will be useful in strengthening the statistical rigor of these
methods and increasing interest in quantitative methods for causal inference and generalizability.
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APPENDIX A: REVIEW OF THE STANDARD (UNWEIGHTED) COX
PROPORTIONAL HAZARDS MODEL
Let uppercase letters denote random variables and lowercase letters possible realizations of random
variables or constants. Let i = 1, . . . , n index the study participants. Let Ti be the time from baseline
to AIDS diagnosis or death, Di be the time from baseline to study drop out, and Ci be the time from
baseline to administrative censoring. In practice, only the minimum of Ti, Di, and Ci is observed,
denoted by T ∗i = min(Ti, Di, Ci). See (Cole and Hudgens, 2010) for a review of univariate survival
analysis methods.
The Cox proportional hazards regression model (Cox, 1972) is one of the most widely used statis-
tical methods in biomedical research. The univariate Cox model is defined as hi(t) = h0(t) exp(βXi),
where hi(t) is the hazard function for individuals with covariate Xi, h0(t) is the reference hazard at
time t for those with Xi = 0, and β is the log hazard ratio for a one unit change in Xi.
Heuristically, Cox regression may be understood as a series of logistic regression models, where at
each ordered survival time, the log odds of the event are regressed on the exposure groups and any
covariates (Efron, 1977). The Cox model is a semiparametric model because no assumption is placed on
the probability distribution for the reference survival time distribution. Equivalently, the function h0(t)
is left arbitrary. The parameters of a Cox model are estimated using maximum partial likelihood (Cox,
1975). Assuming no tied survival times, participant i who had the event at time t contributes the term
exp(βXi)/
∑
j∈R(t) exp(βXj) to the partial likelihood function, where R(t) is the set of participants
at risk at time t. For the case of a single covariate Xi, the partial likelihood is defined as simply a








is an event indicator (i.e., T ∗i = Ti). Only events contribute to the numerator of the likelihood due to
the exponent Yi. There are several ways to handle tied survival times, including methods ascribed to
Peto and Breslow (Peto and Peto, 1972; Breslow, 1974), Efron (Efron, 1977) and an exact approach
(Kalbfleisch and Prentice, 2002), which all return the same results if there are no ties. In the presence
of moderate ties and if time is truly continuous, Efron’s approximation performs well compared to the
other approaches (Hertz-Picciotto and Rockhill, 1997).
One of the central assumptions of the Cox model is that the ratios of the hazards defined by
levels of the covariates are constant over time. This is the proportional hazards assumption. The
proportional hazards assumption can be assessed by fitting the model h(t) = h0(t) exp(β1Xi + β2Xit)
and testing the null hypothesis that β2 = 0, where Xi × t is a product of the covariate and time t.
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, where z1−α/2 is the 1 − α/2 percentile of a standard normal distribution







chi-squared distributed with 1 degree of freedom under the null hypothesis β = 0.
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APPENDIX B: SANDWICH ESTIMATOR OF THE VARIANCE OF THE IPSW
ESTIMATOR
The empirical sandwich-type estimator is used to approximate the asymptotic variance of the IPSW
estimator. Substituting the following empirical estimates for their corresponding quantities in equation
(4.2) produces a consistent sandwich estimator of the variance when β is known. Let θˆ
∗
= (µˆ1, µˆ0)






Ψ∗∆(Yi,Zi, Xi, Si, θˆ
∗
) and












is asymptotically normally dis-
tributed with mean θ∗0 and covariance matrix Σˆ
∗
θ = Aˆ
∗−1Bˆ∗Aˆ∗−T . When β is known, the estimator





θ − 2× Σˆ∗
(12)
θ
and the standard error is sˆe(∆ˆ) =
√
(n+m)−1Σˆ∗IPW .
Similarly, when the weights are estimated, the following expressions can be used to obtain a
consistent sandwich estimator of the variance. Let θˆ = (µˆ1, µˆ0, βˆ) and θ0 = (µ1, µ0,β0). Define the





Ψ∆(Yi,Zi, Xi, Si, θˆ) and
Bˆ = (n+m)−1
∑
i Ψ∆(Yi,Zi, Xi, Si, θˆ)Ψ
∗T
∆ (Yi,Zi, Xi, Si, θˆ). θˆ is asymptotically normally distributed
with mean θ0 and covariance matrix Σˆθ = Aˆ
−1BˆAˆ−T . When β is not known, the estimator of the





θ − 2× Σˆ(12)θ
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